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Abstract: Mycoplasma gallisepticum (MG) is the organism that causes avian respiratory
mycoplasmosis, leading to chronic respiratory disease in chickens and infectious sinusitis in
turkeys (Stipkovits and Kempf, 1996; Levisohn and Kleven, 2000). It is also responsible for
reductions in egg production and other economic losses in the poultry industry (Stipkovits and
Kempf, 1996; Levisohn and Kleven, 2000). Commercially, layer chickens are vaccinated against
MG in the pullet phase before lay. In this dissertation, the potential application of in ovo
vaccination in layer embryos for the subsequent early protection of pullets against field-strain
MG infections was investigated. The use of different sites of injection [air cell (AC) or amnion
(AM)] and various dosages of live attenuated 6/85 (6/85MG) and ts-11 (ts-11MG) vaccine
strains of MG delivered in ovo at 18 days of incubation were evaluated. Vaccine dosages of ts11MG up to 7.25 x 105 CFU did not have negative effects on the hatch and posthatch results.
However, only the 7.25 x 105 CFU dosage had a negative effect on overall BWG. The ts-11MG
was not transmitted from vaccinated to sentinel birds at both the hatch and posthatch periods, and
no subsequent MG DNA or serology responses were detected in response to the vaccine.
Administration of the 6/85MG vaccine at dosages up to 1.73 x 103 CFU did not negatively affect

hatchability or other posthatch variables. Antibody production against 6/85MG through d 42
posthatch with no associated hatch or posthatch mortalities were likewise observed. The high
dose of 6/85MG (1.73 x 104 CFU) resulted in a greater than 15 % mortality at hatch and a greater
than 40 % mortality during the first 2 wk posthatch. Trachea and bronchi lesion scores in the
pullets were significantly increased when they were challenged at d 28 of age with RMG.
However, birds that were in ovo-vaccinated with 6/85MGV exhibited no significant microscopic
lesions due to the RMG challenge. The 1.66 x 103 CFU dosage of 6/85MGV is proposed to offer
the best protection in layer pullets against field-strain MG infections.
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CHAPTER I
INTRODUCTION
Mycoplasma gallisepticum (MG) is a common pathogen in poultry that causes respiratory
illness. It is a bacterium that lacks a cell wall (Yoder, Jr. and Hofstad, 1964; Bradbury, 2005).
The MG organism is responsible for reduced egg production in laying chickens. Common
practice is to vaccinate these birds with a live attenuated MG vaccine during the pullet period.
This serves to help protect the birds from virulent field strains of MG prior to and after transition
to the laying phase. Birds are inoculated either by spray or eyedrop administration (Whithear,
1996). The MG vaccines may be applied via multiple sites, including the eye, nares, or oral
cavity (Evans et al., 2012; Ley, 2003; Leigh et al., 2010). There has been significant success with
in ovo vaccination against a wide range of viral pathogens in poultry (Ricks et al., 1999). There
have also been studies exploring the in ovo-vaccination of layer chickens against field-strain MG
infections using the FMG vaccine (Elliott et al., 2017, 2018, and 2019). The goals of this
dissertation were to explore alternative approaches to MG vaccination, which included the
potential benefit of inoculating layer chickens against MG by the in ovo injection of MG
vaccines of lower virulence than FMG, and to determine their potential efficacy in providing
early protection against field-strain MG infections during the pullet period. The study aimed to
test for the success of the in ovo administration of live attenuated 6/85 and ts-11 vaccine strains
of MG, to determine how well embryos survive the amniotic administration of these live
bacteria, to monitor whether or not they hatch successfully, and to determine if they are able to
1

achieve an earlier humoral immune response and exhibit adequate posthatch development. The
vaccine deemed to have the greatest potential for in ovo use was further tested for its ability to
protect pullets against a virulent field-strain challenge (Rlow-strain of MG). This research may
result in reduced economic and personnel costs, and also result in a reduction in stress associated
with MG vaccination during the pullet rearing period.

2

CHAPTER II
LITRATURE REVIEW
2.1
2.1.1

Avian Egg and Embryo
Avian Embryogenesis
Continued cell growth produces a pointed and thickened cluster of cells (primitive streak)

in the posterior of the embryo as incubation continues (Smith, 2002). This primitive streak
derives from the epiblast of the blastoderm, which then develops into the longitudinal axis of the
embryo. The ectoderm, endoderm, and mesoderm are the germ layers produced by the primitive
streak (Patten, 1920). The ectoderm gives rise to the nervous system, sensory organs, feathers,
claws, glands, and other parts of the epithelial covering of the embryo (Patten, 1920). The
endoderm germ layer differentiates to become the epithelial lining of the organs required for
digestion and respiration. Finally, the epithelial lining of the body cavities, circulatory and
lymphatic system organs, and other fibrous and connective tissues of the developing embryo, all
originate from the mesoderm layer.
During incubation, the three weeks of embryonic development can be differentiated by
three distinct phases. They are commonly referred to as the early, mid, and late (or final)
developmental phases. Early embryonic development (phase 1) begins on the 1 to 7 days of
incubation phase (doi). Formation of the anterior end of the embryo, the lining of the digestive
tract, and the foregut all occur within the first doi (Smith, 2002). By the end of the second day,
the heart and vascular system network have started developing (Tong et al., 2013). The
developments of all the embryonic organs are generally finished by the completion of phase 1.
3

Phase 2, or mid embryonic development lasts from 8 to 14 doi. During this phase,
development of the allantois, amnion, and yolk sac begin. The kidneys become functionally
active by 9 doi. By the 10th day, eggs may be candled to locate and remove cracked and
unfertilized eggs, as well as those that contain dead embryos (Ernst et al., 2004). The feathers,
claws, scales, and appendages among other parts of the embryo also develop during mid
embryonic development (Mellor and Diesch, 2007). The egg tooth forms on the upper mandible,
marking the completion of this phase 2.
Late or final stage embryonic development (phase 3) starts at 15 doi and ends at hatch.
Amniotic fluid begins to regress on day 18 doi, and the yolk sac and its remaining contents are
drawn into the embryo’s body cavity by 19 doi to continue to provide nutrients for the
developing embryo during the final stages of embryonic development. The majority of yolk
uptake occurs via the yolk sac membrane, though smaller amounts of yolk are passed through the
yolk stalk directly into the intestine (Peebles et al., 1998; Yadgary et al., 2010). The yolk sac is
connected to the small intestine via the yolk stalk, which will become Meckel’s diverticulum as
the chick matures. At this point in development, the lungs are also fully functional. The
illustration below shows the daily changes in the morphology and body weight of embryos
during incubation (Figure 2.1).
2.1.2

Embryonic Development Phases
All of the nutritive requirements of the developing avian embryo (with the exception of

oxygen) must be contained within the egg, due to the fact that there is no anatomical connection
to the hen. One of the earliest processes in avian embryonic development is the formation of
special external membranes used for transferring nutrients within the egg, and for carrying out
other essential bodily functions.
4

Avian embryos produce four membranes whose names and functions are listed below:
Yolk sac: encapsulating the yolk, this sac also produces enzymes that convert the yolk
material into a food source that is used by the developing embryo. Any yolk material still in the
yolk sac upon hatching is drawn into the abdomen to continue to supply the chicken with
nutrients for a few days while the chick learns to locate food and how to eat and drink.
Amnion (AM): the AM forms as a fluid-filled sac which protects the embryo as it floats
within the fluid. This creates an environment that can absorb shocks and bumps, allowing the
fragile embryo to develop without harm from impacts or motion. Detailed information regarding
its multiple functions is provided in the following section.
Allantois: circulation of nutrients, oxygen, and waste within the egg is dependent upon
development of the allantois, which creates a circulatory system that is linked with the
circulatory system of the embryo itself, which is driven by the embryonic heart by day 3. When
fully developed, the allantois surrounds the embryo completely and carries out the following
three important functions:
1. Respiration: the allantois oxygenates the blood of the developing embryo and eliminates carbon
dioxide, as the embryo is encased and cannot breathe until hatching.
2. Excretion: as the embryo’s metabolic process begins to produce waste, it removes the wastes and
deposits it in the allantoic cavity.
3. Digestion: as the embryo grows, the allantois moves the albumen and other nutrients, including
calcium from the shell, to the embryo.

Chorion: The chorion connects the inner shell membrane and the allantois, and helping
the allantois in carrying out its functions (Parkhurst and Mountney, 1988).

5

2.2

Amnion
The amniotic membrane differentiates from the ectodermal and mesodermal layers of the

blastoderm, and will eventually encapsulate the entire embryo (Parkhurst and Mountney, 1988).
The amnion is fully developed at 12 doi, and is filled with amniotic fluid, which the embryo
floats in (Patten, 1920). The embryo is dependent on the amniotic fluid to provide several
important functions. The amniotic fluid creates a protective cushion, preventing any physical
trauma to the developing embryo, as well as providing room for the embryo to move around and
change positions as necessary (Patten, 1920). It ensures adequate hydration for the developing
embryo (Romanoff, 1960), and provides the embryo with thermoregulatory protection by
preventing abrupt temperature changes during development (Romanoff, 1960). The amnion also
functions as a storage site for remnants of the albumen, which the embryo usually ingests along
with the amniotic fluid in the later stages of incubation (Romanoff, 1960). Understanding that the
embryo ingests amniotic fluid during incubation has allowed the development of in ovo delivery
of vaccines and nutrients by injection between 17 to 18.5 doi. By delivering the vaccines and
supplemental nutrients into the amnion, it ensures that the embryo will ingest them during
development (Sarma et al., 1995).
A study indicated that if embryos are injected at 16 doi, there was only a 50 % rate of
recovery of the substances found in the organs (Jochemsen and Jeurissen, 2002). However, if one
waits until 18 doi, the injected nutrients can be located in all of the embryonic organs, indicating
that injecting nutrients at 18 doi is more effective as the AM is much more substantial. Amniotic
fluid volume is at its maximum at 12 doi, with its size becoming reduced at 17 doi. After that, the
size of the AM is it its lowest level during the last few days of incubation when it becomes
completely ingested by the embryo (Sarma et al., 1999). Also, embryos this close to hatching are
capable of substantial movement inside the egg, and also consume the AM directly, which helps
6

to distribute those substances throughout the organs and tissues within a day of the injection.
Other researchers have shown that injecting in the AM on day 18 of incubation is quite
successful (Sharma et al., 1984; Sharma, 1986; Jochemsen and Jeurissen, 2002; Weber et al.,
2004; Williams and Hopkins, 2011; Zhai et. al., 2011a, b; Bello et al., 2013; Bello et al., 2014).
2.3

Air Cell
The air cell (AC) is an air-filled space between the egg white and shell, generally located

at the large end of the egg. The internal temperature of freshly laid eggs is normally
approximately 41ºC and has little to no AC (Rahn and Ar, 1980; Carey, 2002; Deeming, 2002;
Durojaye et al., 2019). As the temperature of the egg drops, the liquids contract, separating the
inner shell membrane from the outer shell membrane, forming the AC. Over time, moisture and
carbon dioxide exit the shell through the porous surface, and air replaces them, causing the AC to
increase in volume. It has been reported that relative AC volume in broiler hatching eggs
increased gradually by 8 % from 3 to 12 days of incubation. In addition, AC depth increased by
0.5 cm from 3 to 12 days of incubation (Durojaye et al., 2018). Though the AC typically forms in
the large end of the egg, it can move depending upon the positioning of the egg, and occasionally
they may rupture, producing bubbles inside the egg (Rahn et al., 1974; Rahn et al., 1977). At the
beginning of phase 3 of incubation (day 15 or 16), the chick moves until its head is close to the
AC. The chick will then orient itself lengthwise in the egg, so that by day 18, the head lies
beneath the right wing with its beak pointing upwards towards the AC, allowing it to pierce the
inner shell membrane and inflate its lungs prior to hatching (internal pipping). If the chick is
oriented incorrectly, and internal pipping is not possible, it is very difficult for the chick to hatch.
This in turn would limit its oxygen supply to what it can access through the chorioallantoic
membrane, and would also limit its movement needed to pierce the outer shell. These
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unsuccessful embryos can be identified by the positioning of their feet being oriented towards the
AC (Parkhurst and Mountney, 1988).
2.4

Incubation Conditions
Avian embryos develop best when proper environmental conditions are provided

(Molenaar et al., 2008; Willemsen et al., 2008). Optimum incubational conditions have been
shown to be met with dry bulb temperatures of 37.5 ± 0.5 and wet bulb temperatures of 28.9 ±
0.5 °C (Peebles and Brake, 1987; Bruzual et al., 2000; Pulikanti et al., 2012). Lately, it has been
reported by Durojaye et al. (2019), that mean AC temperature and shell temperature at the
equator on 12 and 18 doi were 38.73 and 38.61oC, respectively. Elibol and Brake (2006) also
indicated that the angle (from the vertical) and rate of daily turning are critical for enhancing
hatchability, as well as reducing the mispositioning of chicken egg embryos for hatching.
2.5
2.5.1

In ovo Application
In ovo Injection
The environments inside commercial chicken houses often create conditions that leave

birds susceptible to infectious agents along with nutritional, environmental, and zootechnical
instabilities. Maintaining successful poultry production and healthy animals depends on
implementing interventions against infectious pathogens such as high pathogenic avian
influenza, Newcastle disease, Marek's disease, infectious bursal disease, infectious bronchitis,
and Mycoplasma gallisepticum (Lister, 2000). In modern poultry operations, vaccination is
currently the most common method to control infectious diseases. An effective vaccination
program requires that all birds in a flock be inoculated, however, it can take several days to reach
the effective levels of humoral and cellular immune responses (Negash et al., 2004).
In ovo vaccination stimulates an early immune response in young chickens (Sharma and
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Burmester, 1982). As an alternative to the posthatch vaccination of chickens, the use of in ovo
vaccinations as becomes common in most broiler operations. This method is used to deliver
vaccines directly into the amniotic sac, encompassing the embryo between 17.5 and 19.25 doi
(Williams, 2007 and 2011). In ovo injection is frequently used for the direct administration of
nutrients or vaccines to embryos in the United States commercial broiler industry. It causes
significantly less stress than the posthatch administration of these materials to hatchlings, and is
a much easier process for poultry industry employees (Williams, 2007). In ovo injection helps to
limit contamination during the vaccination process, and also consistently delivers vaccines to
initiate an early immune response (Williams, 2007). Currently, the commercial poultry industry
utilizes in ovo injection against Marek’s disease (Williams, 2007).
In addition to vaccines, in ovo injection has been used to effectively distribute various
nutrients such as vitamins, minerals, carbohydrates, and amino acids into broiler embryos
(Peebles, 2018). Injecting carbohydrate mixtures containing maltose, sucrose, and dextrin at 17.5
doi into the AM via in ovo injection resulted in increased hatchling BW, 10 d-old chick BW, and
villus surface area in the intestines of Ross 708 broilers (Tako et al., 2004). Additionally,
injecting 20 μg of selenium into the AM of Ross 708 broilers at 18 doi increased their BW when
they were challenged with Eimeria maxima and Clostridium perfringens (Lee et al., 2014). The
selenium delivered by in ovo injection also created an increased inflammatory response as well
as higher serum antibody levels against Clostridium perfringens α-toxin and NetB toxin (Lee et
al., 2014). Administering vitamin C via in ovo injection increased the antioxidant capacity of
broiler chickens as well as their overall performance (Zhang et al., 2019). The in ovo injections
of glycine and proline, or lysine, methionine, and cysteine amino acid mixtures at 14 doi resulted
in increased food consumption and cell-mediated and humoral immunity, along with a decrease
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in the FCR of broilers (Bhanja and Mandal, 2005). In ovo injection of various nutrients has been
shown to affect the performance, small intestine morphology, immunity, and antioxidant activity
of broiler chickens.
2.5.1.1

In ovo Vaccination
Research concerning the effects of in ovo vaccinations against bacterial pathogens is very

limited in the literature (Ricks et al., 1999). In an early experiment in which commercial broiler
chickens were injected in ovo with live Salmonella typhimurium possessing a mutant form of the
aroA gene, it was found that hatch success did not significantly decline when compared with that
of embryos in a control group. It also indicated that the vaccine prevented an increase in
mortality when the birds were exposed to Salmonella typhimurium. However, the bird’s age at
vaccination was not indicated (Coloe et al., 1994). Coloe (2001) later published a patent in which
a gene mutation in Salmonella typhimurium allowed it to be used as an in ovo vaccine. Another
earlier trial was conducted concerning the use of heat-killed Campylobacter jejuni as a vaccine
delivered by in ovo injection. The authors hypothesized that the vaccine would cause an immune
response in the intestinal tract of chicks, thereby reducing Campylobacter jejuni colonization
(Noor et al., 1995). The authors found that when compared to non-vaccinated birds, IgA
antibody production against C. jejuni increased in the intestine and blood of two week-old chicks
that had been vaccinated as embryos.
Most of the published in ovo experiments have involved the injection of live bacteria as
probiotic organisms. These probiotic organisms are introduced as a potential alternative to
antibiotics. However, thus far the results of these experiments have not been promising.
Meijerhof and Hulet (1997) tested a competitive exclusion bacteria product that was
administered into the AC of embryonated eggs at 18 doi. This resulted in a 10 to 13% reduction
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in hatch when compared to a control group. Attempts to dilute their competitive exclusion
culture did not improve hatch. However, thorough and complete experiments have not yet been
performed to test for the effects of dilution on the efficacy of competitive exclusion cultures. In
addition, in the work by Meijerhof and Hulet (1997), birds that had been vaccinated with a
competitive exclusion culture exhibited a high (12.5%) rate of mortality during the first week of
life. In that study, the chicks were challenged with 104 CFU of Salmonella panama at one d
posthatch to test for the efficacy of the competitive exclusion culture vaccine. The chicks
vaccinated in ovo were unable to exclude Salmonella panama in their ceca. Chicks that were
given the competitive exclusion bacteria by spray vaccination at hatch were likewise unable to
exclude S. panama from their ceca.
In a 2013 study by Yamawaki et al. (2013), the effects of placing embryonated eggs in a
culture of various lactobacillus bacteria for 3 minutes at 18 doi for the growth of Salmonella
enteritidis was tested. The study indicated that placement of the eggs in the culture did not
influence hatch success or the exclusion of Salmonella enteritidis from their ceca. Positive
results of in ovo application of competitive exclusion bacteria have been reported in several other
studies. Cox et al. (1992) tested a competitive exclusion culture in the AC or beneath the AC
membranes of embryonated eggs at 17 doi. Results showed that their use improved hatch results.
Hatched birds also exhibited an increase in the exclusion of S. typhimurium when compared to
control chicks. Edens et al. (1997) found that several concentrations of Lactobacillus reuteri
injected into the AC or AM of embryonated eggs at 18 doi did not reduce hatch. The in ovovaccinated birds partially excluded a Salmonella typhimurium challenge at external pipping, but
this ability was reduced at 3 and 6 days of posthatch age. De Oliveira et al. (2014) found that it
was possible to administer 109 CFU of Enterococcus faecium and Bacillus subtilis in ovo

11

without causing a loss in hatch, but also realized, as did Edens et al. (1997), that the continued
use of antibiotics or probiotics administered through the diet would be necessary to maintain
competitive exclusion.
The success of in ovo vaccination is dependent upon the application techniques
employed, the stage of embryonic development at which the vaccine is given, and the site of
vaccine deposition. The in ovo vaccination techniques employed must be easily implemented,
create strong vaccine efficacy, support embryo health, and maintain adequate chick quality
(Williams and Zedek, 2010). Embrex has developed an in ovo injection machine (Embrex
Inovoject system; Zoetis Inc.), which in commercial operations can inject more than 50,000 eggs
per hour, making in ovo vaccination a dependable method of vaccine application (Williams,
2007). However, in ovo injection must be utilized during the correct stage of embryonic
development to allow for the optimal size and position of the embryo for its receipt of an
injection. Developmental stage scores can be used to determine the physiological developmental
stage of the embryo at various time periods in incubation (Sokale et al., 2017). Embrex has
developed a pragmatic developmental stage scoring procedure, which uses predictable
physiological markers and developmental features to create a score ranging from 1 to 7
(Williams, 2007). The embryonic stage score is then used to identify the time period in
incubation during which an injection will be most effective.
2.5.1.2

Site of Injection
Depositing the vaccine into the appropriate site is required for producing an optimal

immune response to the vaccine (Williams and Hopkins, 2011). Injecting vaccines in an
incorrect in ovo site can render the vaccination ineffective, reducing the expected benefits of in
ovo vaccination. Successful in ovo applications depend on the site of injection and the stage of
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embryonic development. Five common sites of injection are the AC, AM, allantois, embryo
body, and the yolk sac (Williams, 2007). The choice of site of injection is dependent upon the
type of immune response that the vaccination is proposed to achieve. It is also important to
remember that conditions inside the egg are changing rapidly during the optimal injection times.
Accidentally mingling waste products and nutrients can be detrimental to the embryo, so
certainty as to the developmental stage of the embryo is important. The site where vaccines and
therapeutic compounds are actually injected in the egg may improve or limit the immune
response to the administered material. Previous research has indicated that the Marek’s disease
vaccine was ineffective when applied to the AC membrane or into the allantoic sac (Williams,
2007). Vaccine injection into the amniotic fluid has proven to provide a much higher protective
index. The vaccine must be injected deep enough to reach the AM, however penetrating too
deeply can cause trauma to the embryo. If not injected deep enough into the egg, it could be
delivered to the AC membrane or into the allantoic sac, rendering a vaccination ineffective. This
is why the precise delivery of vaccines into the proper site of injection is critical for effective in
ovo vaccination programs. The best developmental stage for injecting vaccines is during yolk sac
ascension into the abdomen and before the onset of external pipping. The appropriate time
during incubation for safe in ovo vaccination is between day 17.5 and day 19.25. Injecting prior
to this reduces hatchability by 1-2 % (Williams, 2007).
2.6

Mycoplasma gallisepticum in Poultry
The studies conducted for this dissertation focus on exploring the application of in ovo

vaccination against Mycoplasma gallisepticum (MG), a bacterial pathogen that has significant
negative economic impacts in poultry (Levisohn and Kleven, 2000; Zavala, 2013). The following
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sections provide background information concerning MG and vaccination regimens employed to
protect poultry against MG infection.
2.6.1

Etiology of Mycoplasma gallisepticum
Mycoplasmas are part of a select group of prokaryotes that do not have cell walls,

rendering them difficult to culture and causing them to exhibit slow growth (Kleven, 2003).
Their lack of a cell wall also makes them resistant to antimicrobials, such as penicillin, that act
on cell walls. Avian mycoplasmas are typically isolated on Frey’s or Bradbury’s media, as they
are high in protein and contain animal serum. Though MG is easily overgrown by other
organisms because it is slow growing, an innate resistance to penicillin and thallium acetate
means that these can be used to produce a selective growth media (Kleven, 2003). They have
previously been known as extracellular agents, though more recent research shows that some of
them may be obligatory intracellular parasites (Razin et al., 1998). Mycoplasma taxonomy and
pathogenicity have been examined in more detail elsewhere (Yamamoto, 1990; Razin et al.,
1998; Nascimento, 1991). Mycoplasmas have pathogenicity traits that allow them to survive
within a host, induce disease, and evade immune responses. They adhere to target cells, mediate
apoptosis, cause damage to host cells, mimic antigens leading to tolerance, and suppress T-cell
function and/or production of cytotoxic T cells. The ability of mycoplasmas to stimulate
macrophages, monocytes, T-helper cells, and natural killer cells, can cause them to produce
tumor necrosis factor a (TNF-a), interleukins (IL-1, 2, 6) and interferons (a, b, g). This could
explain the temporary inhibition of the humoral and cellular immune responses and penetration
of lymphoid cells in the respiratory and joint tissues of birds infected with mycoplasma
(Yamamoto, 1990; Razin and Tully, 1995; Razin et al., 1998). Latency is also common to avian
mycoplasmas, and their actions are frequently not manifested until after the host is suffering
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from other disease-causing agents or other weaknesses (Yoder Jr, 1991a; Whitford et al., 1994).
Latency could be explained by the intracellular location of mycoplasmas (Razin et al., 1998).
Research has shown that MG causes immune depression (Nascimento et al, 2003; Silva, 2003),
and mycoplasmas are more likely to be susceptible to mutations than are other bacteria (Ghosh et
al., 1977; Woese et al., 1985). Mycoplasmas are also able to evade the host immune system due
to antigenic variations, enabling them to persist in the host respiratory tract (Markhan et al.,
1994).
2.6.2

Mycoplasma gallisepticum Infection in Layer Chickens
Mycoplasma gallisepticum is the organism that causes avian respiratory mycoplasmosis,

leading to chronic respiratory disease in chickens and infectious sinusitis in turkeys (Stipkovits
and Kempf, 1996; Levisohn and Kleven, 2000), and is responsible for reductions in egg
production and other economic losses in the poultry industry (Stipkovits and Kempf, 1996;
Levisohn and Kleven, 2000). MG infection is responsible for causing symptoms such as
coughing, rales, airsacculitis and poor growth in young chickens. However, the disease is more
commonly responsible for severe secondary infections (usually Escherichia coli), which results
in higher rates of condemnations at processing. MG infection in broiler chickens increases the
effects of any respiratory disorders, substandard housing conditions, and comorbid infections
with other respiratory pathogens, as well as reducing vaccination efficacy. It is not common for
adult birds to show clinical symptoms of infection, but changes in both in egg production and
egg quality can occur (Branton et al., 1988; Ley, 2003).
Mycoplasma gallisepticum has specialized requirements for growth, does not have a cell
wall, and is only found in avian species (Razin et al., 1998). As MG does not seem to live
outside of the host for any sustained time past a few days (Yoder, 1991), reducing contact with
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infected birds such as backyard flocks (McBride et al., 1991), wild birds (Ley et al., 1996;
Fischer et al., 1997; Stallknecht et al., 1998), commercial layer flocks (Mohammed et al., 1987)
and birds that had previously been ill, regardless of whether they had been treated (; Lin and
Kleven 1982a; Glisson et al., 1984; Glisson et al., 1985) is the primary method for curbing
subsequent infections. Studies by Chandiramani et al (1996) and Christensen et al (1996) are
supportive of the possibility that the survival of MG outside the host may actually be longer than
previously assumed. This research suggests that indirect contact is a significant risk for lateral
transmission of MG, which could explain why we see continued outbreaks of the disease despite
increased efforts to control its spread.
Biosecurity solutions can be used to control the exposure of birds to MG by way of direct
and indirect contact. The strength of pathogenicity or virulence in various strains of MG has been
documented (Yoder Jr., 1986; Kleven et al., 1990; Whithear, 1996), and MG seems to have
developed the ability to alter the expression of surface antigens, thereby evading the host
immune response (Boguslavsky et al., 2000; Liu et al., 2001; Kang et al., 2002; Bradbury, 2005).
This ability to alter surface antigen expression may explain the phenomenon of chronic
infections as well as a carrier state, even though the birds generally elicit a strong immune
response (Ley, 2003).
Outbreaks are often caused by vertical transmission or through contact with infected
birds. Transmission of MG, both vertically and laterally, generally occurs throughout the phases
of the illness, when infectious levels in the respiratory tract are highest (Glisson, et al., 1984).
The most common point of entry for lateral infection is the mucous membranes of the respiratory
tract and the eyes (Bradbury and Levisohn, 1996). Transmissions within a flock are often due to
coughing and sneezing, as contaminated droplets enter the eyes and respiratory systems of other
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birds (Bradbury, 2005). An increasing rate of infection within the flock also increases the level
of environmental contamination, thereby exposing the flock to increasing levels of contaminated
fomites, and increasing transmission (Ley, 2003). As both lateral and vertical routes can spread
mycoplasmosis, it is critical that any control program is based on eliminating the disease within a
breeding flock. Sites that contain flocks of varying ages can be difficult to keep free of MG.
Transmission can occur vertically (Lin and Kleven, 1982a; Ley, 2003) despite vaccination
(Glisson and Kleven, 1984; Glisson and Kleven, 1985) or treatment (Ortiz et al., 1995), and
infected birds can maintain carrier status for extended periods of time (Bencina and Dorrer,
1984). Because of this, it is critical to detect infections early to curb transmission.
There are four primary pathogens that are economically important in poultry, although
many other species of mycoplasma are known to occur. The species MG, is associated with
chronic respiratory disease, and is prominent in the United States (Ley, 2003). In the United
States, mycoplasmas constitute significant diseases in the poultry egg industry. A pervasive
infection can devastate a layer or breeder operation, resulting in both direct and indirect losses
during the production cycle (Ley, 2003). Losses can occur due to decreased egg production,
lower rates of hatchability, and increasing costs to medicate flocks. In addition, losses can occur
when attempting to eradicate through culling and sanitizing, or when trying to control infections
via biosecurity, vaccination, and further medication, as well as the costs of employing PCR and
serology tests for monitoring populations.
2.6.3

Mycoplasma gallisepticum and Economy
For both layer flocks and breeder farms, keeping multiple-age flocks on one site is

essential to maintaining the economic viability of the poultry industry, as housing them on
separate farms is cost prohibitive. Recent studies have indicated that the pathogenic
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mycoplasmas can survive outside their host better than expected when one considers their lack of
cell walls, and that their spread by air-borne means has a greater range than previously believed
(Mohammed et al., 1987). As poultry farming often occurs in localized areas, cross-infection
between sites is a substantial risk (Mohammed et al., 1987), making the elimination of direct and
indirect contact exceedingly difficult. Because of these difficulties, biosecurity options that
include isolating flocks is not an appropriate means of reducing transmission of MG. Due to this,
developing effective vaccines against MG has gained renewed interest as a method of
eliminating the disease in multi-aged flocks. There are 3 main purposes for using an MG vaccine
(Fabricant, 1975):
- Protection against respiratory disease
- Maintaining adequate levels of egg production
- Reducing transmission of MG to the egg.
It has also been suggested that the use of MG vaccines can help to eradicate MG within multipleage flocks by limiting infectious reservoirs (Mohammed et al., 1987), and by exchanging virulent
wild strains with milder, less transmissible vaccine variants (Levisohn and Kleven, 1981,
Whithear, 1983).
2.6.4

Mycoplasma gallisepticum Transmission
Ideally, the vaccine strain used should not be able to be transmitted to the chick via the

egg (vertical transmission) or to other flocks (horizontal transmission). Hens in lay vaccinated
with the F-strain of MG (FMG) by eye drop did not show significant signs of it being
transmitted to their eggs, though FMG was noted in 8/352 (2.27%) eggs that were laid during a
seven week period after vaccination (Lin and Kleven, 1982; Glisson and Kleven, 1985).
Nevertheless, the FMG was easily transmitted laterally between vaccinated birds and
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unvaccinated pen mates during the four weeks after vaccination. However, transmission slowed
after that, with some incidence still occurring 27 weeks after vaccination (Kleven, 1981).
Transmission to birds in adjacent pens was recorded, but cross-infection was undetected in flocks
that were physically separated (Kleven, 1981). The FMG vaccine has been used commercially in
Pennsylvania for 30 years. When eleven MG field isolates from unvaccinated flocks in
Pennsylvania were analyzed (Gibbs et al., 1994), the results supported earlier evidence by
Kleven (1981) of a moderately low level of FMG transmissibility. Of the 11 isolates identified,
only one was FMG, which was found on a layer farm documented to have previously used the
vaccine (Gibbs et al., 1994). That study indicated that FMG is no longer a primary cause of
mycoplasmosis in Pennsylvania (Gibbs et al., 1994). However, previously documented evidence
has proven that FMG can be transmitted both within and between sites (Luginbuhl et al., 1967;
Ley et al., 1993). In North Carolina, an MG outbreak in broiler breeder flocks was determined to
be a result of FMG, and a probable source was a nearby commercial layer chicken flock (Ley et
al., 1993). An outbreak of mycoplasmosis in turkeys was also determined to be due to FMG (Ley
et al., 1993).
A study of the transmissibility of mild vaccine strains indicated that the 6/85 strain of
MG (6/85MG) did not infect susceptible birds during 15 weeks of commingling, though they
also had difficulty re-isolating the organism from the vaccinated birds (Ley et al., 1997). To our
knowledge, there are no published studies regarding the vertical transmission of 6/85MG to eggs.
The ts-11 strain of MG (ts-11MG) was isolated in up to 40% of the birds, but failed to transmit
to chickens and turkeys that were separated from the vaccinated birds by a chain-link fence (Ley
et al., 1997). The low transmissibility of ts-11MG has also been shown in other studies. Crossinfection did not occur when 5,000 hens that had not been vaccinated were kept in the same
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house as an equal number of vaccinated hens, and they were only separated by an aisle
(Whithear et al., 1996). After administering ts-11MG directly to the abdominal air sacs near the
ovary of layers, no transmission to the egg was detected. Another study determined that MG was
not detected in 3,750 eggs that were laid by or exposed to hens vaccinated with ts-11MG by eye
drop and by direct contact (Whithear, 1990). Hens vaccinated with ts-11MG by eye drop at 22
weeks of age exhibited no evidence of MG in their eggs or oviducts. However, the organism was
present in both the eggs and oviducts of birds that were vaccinated with the virulent R strain of
MG (RMG) (Kinney, 1993).
2.6.5

Immunity Against MG
There is limited information regarding immune mechanisms operating in MG infections.

There is a possibility that there are different immune responses in relation to the different ways
in which the birds may be exposed. Immunoglobulin (Ig) has been determined to be important,
as bursectomised chickens are less resistant to MG than intact (Adler et al., 1973; Lam and Lin,
1984) or thymectomised (Lam and Lin, 1984) chickens. However, researchers have not been able
to identify a link between levels of protection and the levels of antibodies present (Lam and Lin,
1984; Lin and Kleven, 1984; Talkington and Kleven, 1985; Whithear et al., 1990). Antibodies in
the respiratory tract are most likely important (Chhabra and Goel, 1981; Elfaki et al., 1992;
Yagihashi et al., 1992; Avakian and Ley, 1993; Elfaki et al., 1993), as the dominant Ig class in
respiratory secretions is IgG (Yagihashi and Tajima, 1986; Elfaki et al., 1992; Avakian and Ley,
1993). Circumstantial evidence may exist showing a protective role for cell-mediated immunity
(Adler, 1976), but it has not been proven. Immunity to MG is bursal-dependent (Vardaman et al.,
1973; Kume et al., 1977) although protection is not linked with the level of serum antibodies
(Patten, 1986). Nevertheless, antibodies in respiratory secretions are likely to be significant
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(Whithear, 1986).
An MG infection can be mediated by vaccination when the exposure of poultry flocks to
wild type challenges cannot be eliminated. Killed and live vaccines are being used worldwide for
commercial purposes (Whithear, 1996). The ts-11MG vaccine shows normal growth at 33◦C, but
growth is reduced at 39.5 ◦C (Whithear et al., 1990a,b). A single dose of the ts-11MG vaccine by
eye drop application colonizes the upper respiratory tract and induces long-term immunity
without causing harm (Whithear et al., 1990a,b). It can also be used safely alongside other
respiratory vaccines. High genetic redundancy in MG gives it the ability to accommodate large
amounts of foreign DNA, and recent developments in the genetic modification of mycoplasmas
(Halbedel and Stulke, 2007) have allowed for its usefulness as a vaccine vector.
Studies have shown that cellular immune responses in tracheal mucosa contribute to the
protective immunity that MG vaccines create (Gaunson et al., 2006). A lymphoproliferative
response in the respiratory tract and the over-expression of inflammatory cytokines are primary
characteristics of mycoplasmoses (Razin et al., 1998; Gaunson et al., 2000). However, chicken
IFN enhances heterophil activity and promotes growth in chickens (Johnson et al., 2000; Kogut
et al., 2005). Therefore, introducing IFN into the ts-11MG vaccine may help to enhance cellular
and mucosal immune responses and to promote the growth of chickens.
2.6.6

Mycoplasma gallisepticum Detection
Serology is a common practice that is used to determine if a vaccine elicited an immune

response, even though there is no link between circulating antibodies and MG protection.
However, serology is essential in establishing that a flock has not been previously infected.
Detection of antibodies in tracheal washings can give an accurate measure of immunity, but is
still being researched. Bacterin vaccination stimulates an agglutinin and hemagglutination
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inhibition (HI) response (Talkington and Kleven, 1985). Unfortunately, the antibody response
can decline to insignificant levels (Hildebrand, 1985). A different study has shown that FMG and
an oil emulsion bacterin produce a strong serum agglutination response that continues over a 12week period (Abd-El-Motelib and Kleven, 1993). Conversely, ts-11MG elicits a weaker response
while 6/85MG does not cause any response at all (Abd-El-Motelib and Kleven, 1993).
Nevertheless, ts-11MG can produce a varied and weak, but still detectable, serum antibody
response (Whithear, 1990 a, b). The lack of a detectable serum antibody response is common
when vaccinating with 6/85MG (Evans and Hafez, 1992; Ley et al., 1997).
2.6.7

Commercial Vaccines
Developing an ideal vaccine strain is a complex process and includes many requirements.

It needs to be safe while still being cost-effective. Living vaccines tend to be less safe than are
bacterins, but at the same time adjuvants used in bacterins give rise to food safety and animal
welfare concerns. Not only should live vaccines not inadvertently cause disease, they also should
not transmit disease to other local flocks. Attenuated strains should not be able to return to a
virulent form. A clear marker identifying a vaccine strain from other strains is helpful, and being
able to reliably assess efficacy of the vaccine would be useful as well. The vaccine should
stimulate lifelong immunity from a single dose if possible, and must be of high quality, yet
remain inexpensive to manufacture. The ability to easily and inexpensively store and maintain
the vaccines when not in use is also important. Economic gains from of the vaccine must
outweigh the cost of the vaccination program.
Unfortunately, no known vaccines can fulfill all of these requirements. Today’s
commercial vaccines are found as both whole killed cells (bacterins) or living cultures.
Variations between different strains of MG (Adler and Damassa, 1965; Kleven et al., 1988; Lin
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and Kleven, 1982; Timms and Cullen, 1972) do not to complicate the manufacturing process of
vaccines for multiple uses. However, introducing vaccination as a method for controlling MG
makes it difficult to evaluate flocks using antibody assay procedures. Some vaccines elicit
immune responses that cannot be distinguished from field exposures (Kleven, 1981; Abd-ElMotelib et al., 1993). However, some immune responses to non-virulent live vaccines, including
ts-11MG (Select Laboratories, Inc., Gainesville, Ga) and 6/85MG (Nobilis MG 6/85, Intervet®),
can often be differentiated from those arising from field challenges (Ross et al., 1990; Abd-ElMotelib et al., 1993).
2.6.8

Killed Vaccine
The MG bacterins are commonly used for commercial applications in multiple countries.

These contain inactivated organisms that will stimulate an immune response. They are often
suspended in aqueous oil emulsion (Hildebrand et al., 1983) or aluminum hydroxide adjuvants
(Yagihashi and Tajima, 1986). There have been experiments with new adjuvants, including
liposomes (Barbour et al., 1987, 1988), iota carrageenan (Elfaki et al., 1992, 1993), and immune
stimulating complex (Sundquist et al., 1996). The primary advantage of bacterins is that they are
non-infectious and do not pose a risk of becoming virulent, which can be problematic when
using live vaccines. Unfortunately, these bacterins are costly both in their manufacture and
administration, as it is necessary to apply them to birds individually (Hildebrand et al., 1983).
2.6.9

Live Vaccines
The three living MG vaccines commonly used world-wide include FMG, which is of less

virulence to birds compared to turkeys, as well as 6/85MG and ts-11MG. Both 6/85MG and ts11MG are attenuated strains of low virulence. Live mycoplasma vaccines need to reproduce
sufficiently to stimulate immunity, but not enough to cause disease. Mycoplasma gallisepticum
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often acts synergistically with other infectious agents, which can produce severe disease
conditions. Finding a balance between the virulence of an MG strain and its stimulation of an
immune response is difficult, as there is an inverse relationship (Lin and Kleven, 1982;
Levisohn, 1984; Adler, 1987). Furthermore, avirulent strains do not create much for an immune
response (Levisohn, 1984; Soeripto et al., 1989).
2.6.10

Live Vaccine Origins
It appears that Yamamoto and Adler (1956) were the first to isolate FMG in 1956,

although this is not certain (Levisohn and Kleven, 1981; Khan et al., 1987; Ley et al., 1993).
They initially reported that it was pathogenic to chickens, but that it did respond to antibiotics
(Yamamoto and Adler, 1956). Those characteristics are why it was selected for vaccination
research in the 1960s in Connecticut (Luginbuhl et al., 1967). It has been used extensively in the
field ever since (Levisohn and Kleven, 1981). It is suggested that 6/85MG and the S6 strain of
MG (S6MG) have similarities, but there is no recorded information on their individual origins
(Evans et al., 1992). The ts-11MG vaccine was created from an Australian field isolate (strain
80083), which was attenuated via chemical mutagenesis, and was selected for its temperature
sensitivity (Whithear et al., 1990). The GapA gene is the primary cytadhesin molecule in MG
(Goh et al., 1998; Keeler et al., 1996), and MG attaches to target cells via cytadhesins where
interactions occur with their corresponding host cells receptors (Geary and Gabridge, 1987;
Geary et al., 1989). The GapA gene is expressed in virulent MG strains as well as in FMG,
where it is important for cytadherence and their subsequent virulence properties (Papazisi et al.,
2002). However, the GapA gene is absent in the ts-11MG vaccine strain (Mudahi-Orenstein et
al., 2003), which may make the ts-11MG vaccine less efficient.
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2.6.11

In ovo Results from Previous Research with FMG
The FMG vaccine is most commonly given via aerosol spray, but drinking water and

intranasal administrations have also been successfully employed (Levisohn and Kleven, 1981).
Drinking water applications have produced better responses than spray applications (Carpenter et
al., 1981), with FMG being stable in various diluents, allowing it to be dispersed in drinking
water (Kleven, 1985). Fresh broth and thawed frozen or reconstituted lyophilized cultures have
also provided adequate results (Lin and Kleven, 1984), with concentrations ranging between
105.7 and 109.0 mg/mL (Levisohn and Kleven, 1981; Carpenter et al., 1981). Some lower doses
have likewise been effective during experimental challenge conditions (Lin and Kleven, 1984).
For maximum efficacy, the vaccination of pullets generally occurs between 8 and 18 weeks of
age (Carpenter et al., 1981).
Many previous studies have shown that vaccination of layer embryos against MG at 18
days (d) of incubation (doi), using a live attenuated FMG vaccine at a high dilution or low
bacterial dose, is possible. Embryonated eggs administered FMG via a 10-6 dilution of Poulvac
Myco F (1000 dose vial), at a rate of 1-5 CFU per egg produced hatch results similar to a control
group, but also resulted in variable posthatch mortality (Elliott et al., 2018). Experiments have
shown that FMG creates an immune response in almost all birds, but at higher doses, the birds
fared poorly (Elliott et al., 2018). Birds given higher doses exhibit an increase in mortality and a
significant reduction in body weight. High dosages can be lethal to an embryo or young chick. In
addition to poor health and lower rates of hatch, greater than 50% mortality during the first two
weeks posthatch can occur. It has also been found that birds vaccinated with live FMG were able
to transmit the bacteria to other birds by direct contact. Depending upon whether or not
vaccinated birds exhibit a humoral immune response against FMG, transmission rates have been
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known to vary. Nevertheless, all doses tested resulted in transmission, even when the duration of
contact was limited (Elliott et al., 2019).
In further research, it has been found that the lowest dose of FMG (1-5 CFU) is best, and
shows higher efficacy when the vaccine is given via an in ovo injection machine that utilizes a
disinfection step between each injection (Elliott et al., 2017). Using this procedure, the MG was
still present in the birds 6 weeks posthatch. This suggests that the in ovo vaccination of FMG
could be used in the commercial layer industry without modifying existing in ovo injection
practices. Future research is needed to determine how the performance and immunocompetence
of birds vaccinated in ovo with FMG compare directly in the same study with birds vaccinated as
pullets. It is particularly important to determine if the in ovo-vaccinated birds exhibit an immune
response weeks earlier than birds vaccinated between 9 and 18 weeks of posthatch age. This
would indicate that antibodies are produced earlier before the onset of egg production. In ovo
vaccination could reduce labor costs and the stress of birds, and provide early protection against
MG field-strain infections. Therefore, the purpose of this current dissertation research was to
apply the previous methods employed for earlier FMG vaccine research, but with the use of other
MG strains, such as 6/85MG and ts-11MG. Several treatment variables were tested, including the
site of injection (air cell vs. amnion) and vaccine dosage. Their specific main and interactive
effects on embryo hatchability, mortality, and immunity were evaluated. Also, in ovo-injected
chicks were challenged by a virulent MG strain (R-low MG) to determine if in ovo vaccination
would improve the chick's ability to withstand a virulent MG challenge.
2.6.12

Administration of the 6/85MG and ts-11MG Vaccines Alone or in Combination
with FMG
The 6/85MG vaccine is usually administered via aerosol spray (Evans and Hafiz, 1992),

while ts-11MG is given by eye drop (Whithear et al., 1990). Proper dosing is critical with these
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attenuated strains as slight variations matter. For 6/85MG, a dose of 104 organisms per bird is
not effective, whereas 107 organisms per bird is highly effective (Evans and Hafiz, 1992). The
FMG vaccine has been shown to cause a shift in egg size when used alone (Branton et al., 1999).
However, this shift does not occur when it is used after a previous application of the 6/85MG
vaccine (Leigh et al., 2010). Therefore, 6/85MG may be initially used and then followed with an
FMG vaccine without adverse impacts that are associated with FMG alone. In addition, a study
was conducted to investigate the effects of 6/85MG alone at 10 weeks of age or when overlaid
with FMG at 22 or 45 weeks on bird performance and egg quality. That study showed that there
were no adverse effects on BW, mortality, performance, or egg quality, except for the
yolk/albumen ratio (Viscione et al., 2008 a, b). Birds were necropsied to examine the treatment
effects on their physiological production parameters such as liver lipid and moisture
concentration, ovary weight, and oviduct and small intestine histology. Only liver moisture was
higher in hens vaccinated with 6/85MG alone or overlaid with FMG at 45 wk of age (Viscione et
al., 2009). Peebles et al. (2008) stated that vaccinated laying hens with 6/85MG at 10 wk of age
could experience an increase in plasma protein, and when having received an FMG vaccination
at 45 wk of age, may experience an increase in serum calcium concentration.
For ts-11MG, the recommended dose is greater than 107.7 organisms (Whithear, 1990),
and is highly effective. However, a slight drop in dosage to less than 106.7 organisms per bird
can result in a significant decline in protection (Whithear, 1990). Similar results were found for
an infraorbital sinus challenge (Kinney, 1991; Kinney, 1992). The ts-11MG vaccine has been
used in flocks ranging from 2 to 16 weeks of age (Whithear, 1990). The MS-H strain of MS can
be distributed in the same manner as ts-11MG, and in Australia, it is commonly administered
alongside ts-11MG (Scott et al., 1994). Two trials have been previously conducted to examine
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the influences of FMG vaccine overlays at 22 or 45 wk of age on the effects of a prelay ts-11MG
vaccine at 10 wk of age on the blood characteristics (Peebles et al., 2009) and on the digestive
and reproductive organ characteristics (Vance et al., 2009) of layer chickens. No significant
treatment differences were found for the various blood parameters examined, except for serum
calcium. At 22 wk of age, serum calcium levels were elevated in those birds that received the ts11MG vaccine at 10 wk, and were further elevated when overlaid by the FMG vaccine at 22 wk
of age (Peebles et al., 2009). The digestive and reproductive organs of laying hens were not
impacted by these vaccination treatments, except for vagina length. Vagina length was longer in
hens vaccinated with ts-11MG at 10 wk alone compared to all the other treatments (Vance et al.,
2009). In conclusion, the ts-11MG vaccine may continue providing protection against field strain
MG infections when coupled with an overlay of the FMG vaccine during lay.
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Figure 2.1

Daily changes in the morphological appearance and body weight of a developing
embryo (Parkhurst and Mountney, 1988).
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CHAPTER III
EFFECTS OF THE IN OVO ADMINISTRATION OF THE 6/85 MYCOPLASMA
GALLISEPTICUM VACCINE ON LAYER CHICKEN EMBRYO
HATCHABILITY AND EARLY POSTHATCH
PERFORMANCE
3.1

Abstract
Mycoplasma gallisepticum (MG), the causative agent of chronic respiratory disease in

chickens, has maintained its presence in commercial layer flocks. The 6/85-strain MG (6/85MG)
vaccine exhibits a low level of virulence, is licensed for use in the U.S., and is currently
administered by either spray or eye-drop. In ovo administration as a possible alternative method
of 6/85MG vaccination was assessed. Nine treatment groups, each containing 240 eggs, were
randomly placed on each of 8 replicate flat levels of a single-stage incubator. On 18 days (d) of
incubation (doi), the eggs were administered a particular dosage of a live attenuated 6/85MG
vaccine in either the air cell (AC) or amnion (AM). The treatments included control non-injected
eggs, and eggs injected in the AC or AM with diluent alone, or diluent containing 1.73, 102, or
104 CFU of 6/85MG. Hatchability of injected eggs containing viable embryos (HI) and residual
embryonic mortality were determined at 22 doi. One hatched chick per treatment replicate was
swabbed for the detection of 6/85 MG in the choanal cleft. Six chicks were placed in each of 4
replicate suspended cages per treatment and raised for 3 weeks (wk) for initial posthatch
assessments. On d 21, 6 birds per treatment replicate were swabbed and bled. Swab samples
were analyzed by real-time PCR for the detection of 6/85MG, and blood samples were analyzed
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for MG antibody production by serum plate agglutination (SPA) and ELISA tests. The 104 CFU
dose in the AM group across 6/85MG dosage decreased (P = 0.004) HI, and was associated with
a significant (P < 0.0001) increase in late dead mortality. The HI of the 1.73 x 104 CFU-AM
treatment group was 83.3 %, whereas it was 90 % or greater in all other treatment groups. There
were no significant (P > 0.05) differences for feed intake, body weight (BW), BW gain, or feed
conversion ratio among all treatment groups. Chick mortality during the first 3 wk was 42 % (P
= 0.0001) in the 1.73 x 104 CFU-AM treatment group, but was minimal (< 3 %) in all other
treatment groups. In conclusion, the PCR, SPA, and ELISA tests confirmed that 6/85MG was
only successfully transmitted to embryos in the 1.73 x 102 and 1.73 x 104 CFU-AM treatment
groups, and the highest dose (1.73 x 104 CFU) of 6/85MG injected into the AM adversely
influenced chick hatchability and posthatch survival. Further research is needed to examine the
influence of the 6/85MG in ovo vaccine on layer immune competence.
Key words: embryo, layer, in ovo injection, Mycoplasma gallisepticum, strain 6/85.
3.2

Introduction
According to USDA statistics, a total of 84 million eggs were produced in the United

States, 2018. A major challenge facing the layer industry is Mycoplasma gallisepticum (MG),
which causes huge losses for commercial egg production. The estimated cost of MG infection is
between $118 and $150 million every year (Patterson, 1994). MG is one of the most pathogenic
of the avian mycoplasma diseases in chickens. It is particularly pathogenic in commercial layers
(Ley, 2008). MG has a major impact on the poultry industry economy worldwide. It causes
chronic respiratory disease (Jordan, 1975; Yoder, 1978; Jordan, 1981; Branton et al., 1984;
Kleven, 1998; Levisohn et al., 2000; Bradbury, 2005) in chickens, and infectious sinusitis in
turkeys (Matzer and Yamamoto, 1970). It has been reported that MG affects fallopian tube
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inflammation (Domermuth and Gross, 1962; Domermuth et al., 1967; Nunoya et al., 1997),
which causes losses in egg production (Yoder et al., 1964; Domermuth et al., 1967; Patterson,
1994) and egg quality (Carpenter et al., 1981; Mohammed et al., 1987; Stadelman, 1988; Nunoya
et al., 1997; Ley, 2003). MG also reduces feed efficiency, adding to the cost of its control
(Patterson, 1994; Evans et al., 2005).
In the United States, commercial layers are raised in multiple-age systems and older birds
can pass MG on to younger birds that have not developed strong immune systems (Kleven et al.,
1984; Branton et al., 1997; Kleven, 2008). To control MG infection, MG vaccines have been
released and are used commercially, with limited efficacy against wild MG strains. Live MG
vaccines can be more effective in eliminating egg production losses when they are applied to
layers before field infections (Luginbuhl et al., 1976; Levisohn and Kleven 1981; Yoder et al.,
1984; Cummings and Kleven, 1986; Kleven et al., 1990). Birds vaccinated with the F-strain of
MG (FMG) produce 7 eggs per hen housed more than hens infected with unknown field strains
of MG. In fact, when layers are vaccinated by FMG, egg production and quality, and layer
performance can be impacted (Carpenter et al., 1981). It has been reported that when the 6/85strain of MG (6/85MG) is administrated to hens at 10 weeks (wk) of age via spray, no negative
impacts on egg production, egg size, and ovary function are observed (Viscione et al., 2008).
Also, when pullets were inoculated at 10 wk of age with the ts-11 strain of MG (ts-11MG), no
impact on egg production and size were noted (Vance et al., 2008). In some states, commercial
layer flocks are vaccinated with live FMG. This procedure was approved by USDA in 1988
(Branton et al., 1999). Live MG vaccinations such as ts-11MG (Merial Select, Gainesville, GA)
and 6/85MG (Mycovac, Animal Health, Millsbobro, DE) have been approved in the United
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States but are not as effective as the FMG vaccine (Peebles and Branton, 2012; Throne et al.,
2003).
The virulence of FMG is milder than that of field strains and has been commercially used
as a vaccine at 8 wk of age or older via sprayer or drinker (Carpenter et al., 1981). In fact, FMG
has been successfully administrated by in ovo injection to layer embryos at day (d) 18 of
incubation (doi) (Elliott et al., 2018). Nevertheless, although the FMG vaccine is commercially
used, it is more virulent compared to the 6/85MG and ts-11MG vaccines (Peebles and Branton,
2012). When the 6/85MG or ts-11MG vaccines are administered by in ovo injection at 18 d of
incubation, they have the potential to elicit an early embryo immune response, improve
hatchability, lower bird stress, and reduce labor and vaccine costs. In addition, in ovo
administration of the 6/85MG and ts-11MG vaccines may not result in a delay in egg production,
cause changes in egg size, or result in a temporal post-peak drop in egg production, as does the
FMG vaccine (Burnham et al., 2002a).
Mycoplasma gallisepticum vaccine applications are used in different sites such as the eye,
nares, or oral cavity (Ley, 2003; Leigh et al., 2010; Evans et al., 2012). MG vaccines can also
used via water lines. However, it has been reported that vaccination administered by eye drop or
spray leads to a faster immune response compared to other sites or methods (Purswell et al.,
2010). In ovo injection has been used in broiler hatching eggs since the 1990’s for the Marek’s
disease vaccine. In the United States, Embrex, Inc. manufactures the Inovoject automatic multiegg in ovo injector (Ricks et al., 1999). In ovo injection has been used for the delivery of
different biologics such as probiotics (De Oliveira et al., 2014) and carbohydrates (Zhai et al.,
2011). In ovo vaccination of FMG (Elliot et al., 2018) is relatively new but is a promising
method to control MG infections at an early phase of hatchling age (El-Safty et al., 2005). This
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method could minimize bird stress during vaccination and save labor and vaccine costs. In fact,
injecting MG vaccines in ovo may reduce potential harmful effects when compared to regular
MG vaccination practices. However, there is no published data evaluating the effects of the
6/85MG vaccine delivered by in ovo injection on layer hatchability and survivability.
Furthermore, the optimum dosages and sites of injection, for its improved efficiency have not
been evaluated. Therefore, the objectives for this study were to examine the effects of the in ovo
vaccination of a live attenuated 6/85MG vaccine administered at different dosages and at
different sites [ air cell (AC) and amnion (AM)] in live embryonated eggs on hatchability and
pre- and posthatch livability, and to also investigate its effects on hatchling and posthatch
immune responses.
3.3
3.3.1

Materials and Methods
Egg Incubation
A total of 2,160 fertile Hy-Line W-36 layer eggs, that were obtained from a 25 wk-old

MG-clean commercial breeder flock (Hy-Line Company, Mansfield, GA). Eggs were incubated
at 37.5◦C dry bulb and 29.0◦C wet bulb [53 % relative humidity (RH)] temperatures for the first
18 d of incubation (doi). Three HOBO temperature/RH data loggers (Onset Computer
Corporation, Bourne, MA) were placed in the top, middle, and bottom tray levels of the
incubator to accurately record environmental conditions. An Avida AH1-165-16 single stage
incubator (Chick Master incubator Company, Medina, OH) was used for both the setter (0-18 d)
and hatcher (18-22 d) incubation phases.
3.3.2

Treatment Designation and Application
The treatments included control non-injected eggs, and eggs injected in the AC or AM

with Poulvac Marek’s disease diluent (Zoetis, Parsippany, NJ) alone, or diluent containing one of
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3 different levels of 6/85MG (NOBILIS® MG6/85, Intervet International, Boxmeer,
Netherlands). The 6/85MG vaccine was resuspended and diluted in 50 mL of diluent. The 1x10-6
dilution of the live 6/85MG vaccine prepared on the same d of injection contained 173 CFU of
the organism in each 50 μL volume of solution that was injected into each egg. In addition, the 1
x 10-4 and 1 x 10-2 dilutions respectively contained 1.73 x 102 and 1.73 x 104 CFU of the
organism in each 50 μL volume of solution that was injected into each egg (Table 3.1). Groups
of 30 eggs belonging to each of 9 pre-assigned treatment groups were randomly arranged within
each of 8 replicate tray levels of the setter unit. At 12 doi, infertile eggs and those containing
dead embryos were removed and only those eggs containing viable embryos were vaccinated at
18 doi. All in ovo injection treatments were administered at 18 doi using an Embrex Inovoject M
automated multi-egg injector (Zoetis, Parsippany, NJ). Before injection, the 6/85MG vaccine
was plated on Frey’s Mycoplasma agar (Frey et al., 1968) and incubated at 37° C to confirm
vaccine viability and the actual dosage being delivered. A total of 72 eggs (one egg from each
treatment group on each replicate tray level) were injected with Coomassie brilliant blue R-250
dye (Genlantis, San Diego, CA) and opened to locate the site of injection including the AC, AM,
body proper, and yolk sac, and the stage of embryonic development using the Embrex embryo
stage scoring procedure (Sokale et al., 2017).
Eggs were transferred to hatching baskets after injection. Eggs from each treatment group
were randomly allocated to 4 sections within each of 2 hatching baskets to coincide with the
treatment replicate groups represented in the setter. Diluent-injected control (AC and AM) eggs
were incubated in a separate hatcher unit from that containing the non-injected and 6/85MGinjected eggs in order to prevent possible 6/85MG cross-contamination of the diluent-injected
control eggs. Both hatchers were located in the same room and were set at the same temperature
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and humidity [36.7°C dry bulb and 28.3°C wet bulb (55 % RH)] for the entire hatcher period.
Similar to that in the setter, the temperature and humidity of the both hatcher units were
monitored by HOBO loggers to insure an accurate reading of the environmental conditions.
Hatching baskets containing eggs that received the high (1.73 x 104 CFU) 6/85MG dosage were
stacked at the bottom of the hatcher, with the medium dose (1.73 x 102 CFU) eggs in the middle,
and the low dose (1.73 CFU) eggs at the top portion of the hatcher, to eliminate crosscontamination via chick droppings. The incubators and data loggers were monitored daily to
insure their proper function and that the eggs were incubated under optimum conditions.
3.3.3

Air cell and Amnion Injection
Before plastic gapping sleeves were placed on all injector machine needles to target the

AC, AM control treatment eggs was injected with diluent. This also allowed the AC of the eggs
in the control treatment to be injected with the diluent. Control group eggs were placed in the
incubators before the MG-vaccinated eggs to prevent cross contamination. The 6/86MG vaccine
was applied in the AC of eggs in sequence from the lowest to highest dosage, and a cleaning
cycle was applied between each individual dosage treatment. The gapping plastic sleeves were
then removed and a full cleaning cycle was run before applying the 6/85MG vaccine in the AM
treatment group. In the AM treatment group, the 6/85MG vaccine was likewise injected
sequentially from the lowest to highest dosage. Eight eggs from each treatment were tested for
injection accuracy and all exhibited successful injections into the site intended (AC or AM).
Hatch success and residual embryonic mortality were determined at 22 doi.
3.3.4

Sampling at Hatch
Hatched chicks were counted and weighed and only females were used in the posthatch

phase of the study. Residue eggs were marked, counted, and subsequently opened for embryonic
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development stage confirmation (Mauldin and Wilson, 2014). Percentage egg weight loss
(PEWL), hatchability of injected eggs containing viable embryos (HI), and hatchling body
weight (BW) were measured. Bird husbandry, handling, sampling, and euthanasia procedures
were approved by a USDA-ARS Animal Care and Use Committee (Mississippi State, MS). A
subset of 8 chicks were randomly chosen from each flat (total of 72 chicks), and were then were
euthanized, and their choanal clefts were immediately swabbed for 6/85MG detection using prewetted sterile swabs in phosphate-buffered saline. Controls, and 1.73, 102, and 104 CFU dosage
treatment groups were swabbed in that order. All swabs were suspended in 100 μL of phosphatebuffered saline and extracted using a BioSprint 96 One-For-All Kit (Qiagen, Valencia, CA). All
swab samples were run in duplicate using a 7500 Fast Real Time PCR System (Applied
Biosystems, Foster City, CA). A specific MG primer and probe were used for DNA analysis. A
25 μL sample volume was used for PCR testing, which included 2.5 μL of forward primer, 2.5
μL of probe, 12.5 μL of Taqman Universal Master Mix (Applied Biosystems, Foster City, CA),
and 2.5 μL of extracted DNA in sterile water (Raviv et al., 2008). A 22.5 μL volume of master
mix was loaded into each well of a 96-well-plate, and 2.5 μL of sample DNA was then
subsequently added to each well. Each plate included a negative control that contained sterile
water only, and a positive control containing Rlow-strain MG (RMG) to design a standard curve
including 10-1, 10-2, and 10-3 dilutions. The qPCR cycling process used was as described by
Raviv et al. (2008).
3.3.5

Posthatch Bird Raising and Sampling
Chicks from each replicate flat in each treatment group were pooled. The chicks were

raised to 3 wk of age in suspended battery cages that were housed in one room. Each battery
cage measured 0.76 m x 0.46 m (0.35 m2). Chicks from a pool of 216 in each of the non-injected,
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diluent-injected, and MG-vaccinated treatment groups were randomly selected and placed in
each of 4 replicate cages belonging to each of the 9 treatment groups. Stocking density was 0.06
m2 per bird to meet Hy-Line W-36 breeder pullet recommendations (Hy-Line Red Book, HyLine International, 2014). There were 2 separate lines of cages in the room, with non-injected
and diluent-injected control birds placed in the right wing and 6/85MG-treated birds placed in
the left wing of the room. Each cage had 2 nipple drinkers, and birds were provided a bottom
cage liner and a plate of feed for the first week. After the first wk, the birds were fed using
hanging feeders. All birds had free access to water and feed during the grow-out period. The
pullets were fed a crumble starter diet that met the recommended NRC requirements (NRC,
1994). According to Hy-Line recommendations for W-36 pullets, the lighting program provided
21 hours (h) of light and 3 h of dark in the room during the first wk, and 20 h of light and 4 h or
dark until d 21 of age. Furthermore, as recommended, room air temperature was 34◦C on the first
d and was lowered by 2 to 3◦C daily until 21◦C was reached. Birds belonging to the control
treatments were monitored daily before those belonging to the 6/85MG treatments in order to
prevent cross-contamination. Birds in the 1.73, 102, and 104 CFU dosage treatment groups were
monitored daily, in that respective order, to further prevent cross-contamination. Chick mortality
was monitored daily and dead chicks were weighed on a daily basis. Mean bird BW for each
treatment replicate cage was measured on d 0, 7, 14, and 21 posthatch, and BW gain (BWG) was
determined in the 0-7, 7-14, 14-21, and 0-21 d intervals. At 3 wk of age, all birds were swabbed
in the choanal cleft to test for the presence of 6/85MG. The protocol by Nascimento et al. (1991)
was used for 6/85MG detection by PCR.
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3.3.6

Blood Sampling and Immunology
After the birds were swabbed at 3 wk of age, they were immediately bled. After serum

extraction, one drop of MG antigen was added to each individual 30 μL volume of serum. The
mixes were shaken on a Clinical Rotator (Fisher Scientific, Hampton, NH) for 3 to 5 min. Serum
agglutination indicated that IgM antibodies against MG were present in the sample. Only SPApositive samples were further analyzed by ELISA for the presence of IgG antibodies against
MG.
3.4

Statistical Analysis
A randomized complete block design was employed for the hatch results, which included

hatchability, egg residue analyses, and hatchling BW, where incubator tray level was considered
as the blocking factor. All treatments were randomly assigned to each block (tray level). Those
treatments housed in the same incubator were compared statistically. Statistical comparison of
the AC and AM diluent-injected control treatments were analyzed separately from the noninjected and 6/85MG injection treatments, as they were housed in separate incubators. Posthatch
BW, MG DNA detection by qPCR, and MG antibodies detected by SPA and ELISA tests were
analyzed using a completely randomized experimental design, where replicate cage was the
experimental unit. A 3 dosage x 2 site of injection factorial arrangement of treatment was used
for the hatch data of the 6/85MG treatment groups housed in the same incubator and for the
posthatch results of the 6/85MG treatment groups in the grow-out facility. A one-way ANOVA
was used to compare the AC and AM diluent-injected treatments and to individually compare the
non-injected treatment group with each of the 6/85MG treatment groups. All variables were
analyzed by SAS 9.4 (SAS Institute, 2014) employing PROC MIXED, and means separations
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were performed using Fisher’s protected least significant difference. Statements of significance
were based on P ≤ 0.05 unless otherwise stated.
3.5
3.5.1
3.5.1.1

Results and Discussion
Hatch Variables
Comparison of Site of Injection (AC and AM) Treatments in Diluent-Controls
The data for the AC and AM diluent-injected treatment groups were analyzed separately

because they occupied a separate hatcher that was used in order to prevent 6/85MG crosscontamination. In the diluent-injected controls, there were no embryo mortalities in either the AC
or AM treatment groups. There were also no significant differences due to site of injection (AC
and AM) treatment for PEWL in the 0-12 (P = 0.694), 12-18 (P = 0.654), and 0-18 (P = 0.931)
doi intervals; HI (P = 0.777); hatchling BW (P = 0.964); and post-injection pre-pipped (P =
0.429) and pipped (P = 0.929) embryonic mortalities. No hatched chick mortalities were
observed in either site of injection treatment. The mean ± SEM for the respective AC and AM
site treatments for the above variables were: 0-12 PEWL (7.13 ± 0.14 % and 7.21 ± 0.14 %); 1218 PEWL (4.08 ± 0.08 % and 4.03 ± 0.08 %); 0-18 PEWL (11.25 ± 0.19 % and 11.23 ± 0.19 %);
HI (92.98 ± 1.38 % and 92.40 ± 1.38 %); hatchling BW (35.35 ± 0.34 g and 35.37 ± 0.34 g);
post-injection pre-pipped (1.44 ± 1.01 % and 2.29 ± 1.01 % ) and pipped (4.54 ± 1.51 % and
4.68 ± 1.51 %) embryonic mortalities. These results indicate that PEWL, HI, hatchling BW, and
percentage late embryo and early hatchling mortalities did not differ whether or not diluent was
injected into the AC or AM. Therefore, the site of injection had no influence on the effect that
the injection process itself had on eggshell porosity or the development and hatching success of
the embryos. The subsequent reports of the effects of the site of injection in Tables 3.2 – 3.5,
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therefore, may be attributed solely to the 6/85MG itself and not the diluent in which it was
suspended.
3.5.1.2

Comparison of Non-Injected Controls with Individual Site of Injection-6/85MG
Dosage Combination Treatments
In the incubator in which both non-injected and the 6/85MG-injected eggs were

incubated together, the non-injected treatment group was individually compared to each of the
site of injection-6/85MG dosage combination treatment groups. Fatemi et al. (2020) showed that
the hatch results of non-injected control eggs did not differ from diluent-injected controls.
Therefore, it is suggested that the diluent-injected controls in this study would have compared
similarly to each site of injection-6/85MG dosage treatment combination, as did the non-injected
controls. There were no significant differences between non-injected controls and each site of
injection-6/85MG dosage treatment combination for PEWL in each of the 3 intervals; hatchling
BW; or for post-injection pre-pipped embryonic mortalities. However, HI, pipped embryonic
mortality, and hatched chick mortality in the non-injected treatment was significantly different
from only one of the site of injection-6/85MG dosage treatment combinations. Non-injected
controls showed significantly lower values than the 1.73 x 104 CFU-AM treatment combination
for HI (P = 0.005), pipped embryo mortality (P = 0.030), and hatched chick mortality (P =
0.001). The mean ± SEM for the above variables in the non-injected treatment group were: 0-12
PEWL (7.30 ± 0.10 %); 12-18 PEWL (3.96 ± 0.08 %); 0-18 PEWL (11.30 ± 0.17 %); HI (92.60
± 2.06 %); pre-pipped (1.39 ± 1.71 %) and pipped (4.84 ± 2.32 %) embryo mortalities; and
hatchling BW (34.22 ± 0.31 g). No hatched chick mortalities were observed in the non-injected
control group.
These results confirm that the 1.73 x 104 CFU-AM treatment combination has a proven
negative impact on the normal hatching process. The 1.73 x 104 CFU-AM treatment combination
58

did not affect hatchling BW. This was in agreement with Elliott et al. (2017), who found that the
in ovo injection of 1.73 x 104 CFU of FMG per egg had no negative impact on hatchling BW,
when compared to non-injected or diluent-injected controls. Nevertheless, the 104 CFU-AM
treatment negatively impacted HI, and pipped embryonic and hatched chick mortalities. In this
current study, the HI, pipped embryonic mortality, and hatched chick mortality rates in the 1.73 x
104 CFU-AM treatment group were 82.78 %, 2.70 %, and 6.85 %, respectively. However, in the
study by Elliott et al. (2017), the HI of eggs injected in ovo with 2.4 x 104 CFU of FMG was
75.00 %. Furthermore, Elliott et al. (2017) reported that the pipped embryo mortality and hatched
chick mortality rates in the 2.4 x 104 CFU treatment group were 16.7 % and 25.0 %, respectively.
The embryo and hatchling mortality rates in response to FMG were, therefore, much higher
compared to those in response to 6/85MG at the same doses. These differing results could be
attributed to the greater virulence of FMG compared to that of 6/85MG. Because the hatch
results of the non-injected controls were only different from the 1.73 x 104 CFU-AM treatment,
this would also indicate that the injection of the 102 or 173 CFU doses in the AM are safe.
Therefore, it is recommended that when 6/85MG injections are given in the AM, the doses
should be less than 1.73 x 104 CFU. Although the AC site was safe at all the doses, the AC site
did not allow for bacterial transmission to the embryos.
3.5.1.3

Main and Interaction Effects of site of Injection and 6/85MG Dosage
Treatments
For the eggs injected with 6/85MG, there were no significant main or interactive effects

due to dosage or site of injection treatment for PEWL between d 0 and 12, 12 and 18, and 0 and
18, or for hatchling BW. However, there was a significant (P = 0.009) site of injection x dosage
interactive effect on HI, where chicks in the 104 CFU-AM treatment combination experienced a
significantly lower (approximately 9.00 % or more) HI in comparison to all the other treatment
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group combinations (Table 3.2). There were no main or interactive effects involving 6/85MG
dosage for post-injection pre-pipped (18 to 22 doi) embryo mortality, but there was a significant
(P = 0.032) main effect due to site of injection (AC and AM) (Table 3.3). Pre-pipped embryo
mortality was significantly increased when eggs were injected in the AM rather than the AC.
There was also a significant (P=0.008) dosage x site of injection interaction for hatched (d 22
doi) chick mortality. Hatched chick mortality was significantly increased when 104 CFU of
6/85MG was injected in the AM (Table 3.3). These combined results suggest that injection of the
vaccine in the AM can increase embryo mortality during the hatching process, particularly when
the highest (104 CFU) dosage of the 6/85MG vaccine is used. This effect may have been caused
by the high bacterial population that was injected, particularly during the hatching phase, which
is well known as a very stressful period for the embryo. In addition, in ovo injection of 1.73 x 104
CFU of the 6/85MG vaccine in the AM may cause respiratory distress by reducing the amount of
oxygen delivered to the hatchling. This same suggestion has been given by Elliott et al. (2018) to
describe and explain the effects of various dosages of the FMG vaccine administered by AM
injection in layer eggs.
The 6/85MG vaccine has not been applied in ovo prior to this current study. The vaccine
was injected in the AC and AM to determine if it could be administered via either site
successfully and safely. The AC site was also chosen in order to test if it would be a better site
than the AM for a more gradual and safer absorption of the 6/85MG vaccine. However, the hatch
results showed that AC site of injection did not allow for any bacteria to be successfully
transmitted to the embryo. Application of the vaccine in the AC would only allow the chick to
make later contact with the organism during the pipping process, making systemic colonization
of the bacterium in the chick less probable. The results of the current study are in agreement with
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Williams and Hopkins (2011), who showed that when the Marek’s disease vaccine was delivered
in the AC, the vaccine was not taken up by the embryo. In general, at 18 doi, the embryo imbibes
and aspirates the amniotic fluid by the exertion of negative pressure on the AM (Romanoff,
1960). Therefore, in ovo injection into the AM rather than the AC allows for more direct
systemic entry of the organism into the embryo. Cummings and Kleven (1986) and Kleven et al.
(1998) have likewise reported that AM injection of the live FMG vaccine leads to colonization of
FMG in chicken trachea. In fact, the AM injection of 1.73 x 102 CFU of the 6/85MG vaccine
produced better results in comparison to the AM injection of the FMG vaccine at the same
dosage that was employed by Elliott et al. (2017).
3.5.2
3.5.2.1

Posthatch Variables
Comparison of Site of Injection (AC and AM) Treatments in Diluent-Controls
As previously described, the data for the AC and AM diluent-injected treatment groups

were analyzed separately because they were incubated a separate hatcher that was used in order
to prevent 6/85MG cross-contamination. In diluent-injected controls, there were no significant
differences due to site of injection (AC or AM) for BW at 0 (P = 0.670), 7 (P = 0.969), or 14 (P =
0.102) d posthatch. However, BW on d 21 posthatch was significantly (P = 0.046) higher in the
AM in comparison to the AC treatment. There were also no significant differences for BWG in
the 0-7 (P = 0.168), 7-14 (P = 0.301), 14-21 (P = 0.0570), and 0-21 (P = 0.078) d intervals, and
for total bird morality between 0 and 12 d posthatch (P = 0.134). In the diluent-injected group,
the mean ± SEM for the respective AC and AM site of injection treatments for the above
variables were: d 0 BW (35.30 ± 0.560 g and 35.50 ± 0.560 g); d 7 BW (62.6 ± 7.39 g and 62.9 ±
7.39 g); d 14 BW (110.50 ± 3.11 g and 116.50 ± 3.11 g); d 21 BW (176.00 ± 3.98 g and 186.00 ±
3.98 g); 0-7 d BWG (22.25 ± 3.82 g and 28.25 ± 3.82 g); 7-14 d BWG (45.75 ± 6.41 g and 53.00
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± 6.41 g); 14-21 d BWG (66.00 ± 1.41 g and 69.00 ± 1.41 g ); 0-21 d BWG ( 136.40 ± 5.92 g
and 150.35 ± 5.92 g); and total bird mortality through 12 d posthatch (16.50 ± 9.53 % and 0.00
± 9.53 %). These results indicate that other than BW at d 21 posthatch, injection of the vaccine
diluent into either site (AC or AM), had no overall influence on bird posthatch performance
through d 21. Nevertheless, in the diluent-injected controls, the greater BW on d 21 observed in
the of AM-treated in comparison to the AC-treated birds could be due to a better absorption of
diluent and a subsequent greater promotion of nutrient utilization and growth when diluent is
injected in the AM rather than the AC. This suggestion is in agreement with Zhai et al. (2011),
who showed that when commercial diluent was injected into the AM, it increased the absolute
and proportional BW of broiler hatchlings.
3.5.2.2

Comparison of Non-Injected Controls with Individual Site of Injection-6/85MG
Dosage Combination Treatments
As previously described, in the incubator in which both non-injected and the 6/85MG-

injected eggs were incubated together, the non-injected treatment group was individually
compared to each of the site of injection-6/85MG dosage combination treatment groups. There
were no significant differences between non-injected controls and each site of injection-6/85MG
dosage treatment combination for BW at d 0 (P = 0.578), 7 (P = 0.407), 14 (P = 0.291), and 21 (P
= 0.398); or for BWG in the 0-7 (P = 0.392), 7-14 (P = 0.485), 14-21 (P = 0.328), and 0-21 (P =
0.384) d intervals. However, total chick mortality through 12 d posthatch in the non-injected
treatment group was significantly (P = 0.0001) different from only one of the site of injection6/85MG dosage treatment combinations. Total chick mortality through d 12 posthatch was
significantly higher in the 1.73 x 104 CFU-AM treatment combination in comparison to noninjected controls. The mean ± SEM for the above variables in the non-injected treatment group
were: d 0 BW (34.00 ± 0.52 g), d 7 BW (57.78 ± 6.21 g), d 14 BW (115.75 ± 3.54 g), and d 21
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BW (179.75 ± 9.31 g); 0-7 d BWG (23.50 ± 4.50 g), 7-14 d BWG (59.25 ± 6.52 g), 14-21 d
BWG (63.75 ± 7.33 g), and 0-21 d BWG (143.83 ± 9.28 g). No chick mortalities were observed
in the non-injected control group. Fatemi et al. (2020) showed that the posthatch performance of
broiler chicks hatched from non-injected control eggs was not different from those hatched from
diluent-injected control eggs. Based on those previous results, it is suggested that the
performance of broiler chicks hatched from eggs belonging to the non-injected control group
would also not be significantly different from those hatched from eggs belonging to the diluentcontrol group in this study. The posthatch results of non-injected controls were not different from
all the site of injection-6/85MG dosage combination treatment groups, except for the 1.73 x 104
CFU-AM treatment, which indicates that the injection of the 102 or 173 CFU doses in the AM
are safe. Although the AC site was safe at all the doses, it did not allow the transmission of
bacteria to the embryos. These results confirm that although the 104 CFU-AM treatment
combination did not affect the growth of viable chicks, it has a proven negative impact on chick
livability through 12 d posthatch. Therefore, it is suggested that when 6/85MG injections are
given in the AM, that dosages should be less than 104 CFU.
3.5.2.3

Main and Interaction Effects of Site of Injection and 6/85MG Dosage
Treatments
There were no significant main or interaction effects due to site of injection and 6/85MG

dosage on BW and BWG at all the specified times during the grow out period (Table 3.4). The
results of the current study are in agreement with Viscione et al. (2008), who observed no
negative effects on layer BW and BWG between 20 and 47 wk of posthatch after the gavageinoculation at 10 wk posthatch pullets with 106 CFU of 6/85MG. The results of this study and
that of Viscione et al. (2008) indicate that whether or not 6/85MG is administered by in ovo
injection or later in the prelay pullet period, that bird growth is not adversely affected. However,
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there was a significant (P = 0.012) site of injection × 6/85MG dosage interaction for total chick
mortality through d 12 posthatch in the current study (Table 3.4). Subclass means comparisons
showed that mortality was higher in the 1.73 x 104 CFU-AM treatment group in comparison to
all other site of injection-6/85MG combination treatments. Bird mortality in the 1.73 x 104 CFUAM treatment was 41.65 %, whereas it was 0.00 % in all other groups (Table 3.4). Furthermore,
birds from the 1.73 x 104 CFU-AM treatment group showed extended and twisted neck breathing
(Figure 3.1). The 1.73 x 104 CFU-AM treatment may have affected the tracheal and lung
functions of the chicks due to its increased level of colonization, and a subsequent increase in
respiratory failure. Levisohn et al. (1983) did not report the results of the effects of FMG or
virulent RMG infections introduced at 14 d of age on broiler chick mortality. Nevertheless, they
did observe similar results to that of Viscione et al. (2008) for broiler BW between 0 and 12 d
after a tracheal FMG inoculation. Minimal numerical (non-significant) decreases in BW occurred
after the birds were introduced to 3.2 x 108 FMG organisms per mL. However, significant
marked depressions in broiler BW were observed at 8 and 12 d after the tracheal inoculation of
3.0 x 108 RMG organisms per mL. When Viscione et al. (2008) gavage-inoculated pullets with
6/85MG at 10 wk of age in conjunction with FMG at 22 or 45 wk of age, there were no
subsequent impacts on BW or mortality between 20 and 47 wk of posthatch age. The results of
Levisohn et al. (1983) and Viscione et al. (2008) are similar concerning the effects of a pre-lay
inoculation of FMG on subsequent BW, and show that despite differences in bird type and the
doses and timing of FMG inoculation, it has minimal effects on BW in the early phases of
growth as well as after sexual maturity.
In a subsequent study by Elliott et al. (2018), it was reported that the in ovo injection of
2.4 x 102 CFU of FMG caused commercial layer chicks to experience over a 50 % mortality
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within the first 2 wk posthatch. In addition, Elliott et al. (2018) observed that the posthatch BW
of birds belonging to the 102 and 104 CFU FMG in ovo treatment groups were significantly lower
compared to those given lower dosages and to those in a diluent-injected control group.
Conversely, in the current study, the in ovo injection of 102 CFU of 6/85MG did not affect chick
BW and did not lead to an increase in posthatch chick mortality. Furthermore, the AC or AM
injection of the live 6/85MG vaccine at any of the dosages employed in this study had no effect
on layer chick BW or BWG through 3 wk of posthatch age. The differing results between this
study and that of Elliott et al. (2018) are related to the greater virulence of FMG, and that
6/85MG is essentially avirulent.
3.5.2.4

Hatch and Posthatch DNA Detection and Immune Response to 6/85MG
The PCR results of the choanal cleft swabs taken from chicks belonging to the non-

injected control group at hatch and at 3 wk posthatch were negative for MG. The serum samples
taken at these times from that same control group for SPA analysis also tested negative for IgM
against MG. Birds in the diluent-injected groups showed similar results at hatch and in the
posthatch period (data not shown).The PCR results of the choanal cleft swabs taken at hatch, and
for the IgM and IgG serologic responses at 3 wk of age, are shown in Table 3.5. There was a
significant (P = 0.015) main effect due to 6/85MG dosage for the percentage of birds that tested
positive for the presence of MG DNA at hatch. Furthermore, there was a significant (P ≤ 0.0001)
main effect due to site of injection for the percentage of birds that tested positive for the presence
of MG DNA at hatch. A significant (P ≤ 0.0001) main effect due to site of injection was likewise
observed for a serologic IgG response to MG at 3 wk posthatch. Significant (P ≤ 0.0001)
6/85MG dosage × site of injection interaction effects were observed for the percentage of birds
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that tested positive for the presence of MG DNA at 3 wk posthatch and for a serologic IgM
response to MG at 3 wk posthatch (Table 3.5).
The percentage of birds that tested positive for the presence of MG DNA at hatch was
higher in the 1.73 x 104 CFU treatment group in comparison to both the 173 and 102 CFU
treatment groups. Those in the 1.73 x 102 CFU treatment group were also higher than those in
the 1.73 CFU treatment group. The percentage of MG DNA in chicks at hatch was found to be
significantly higher (50 % increase) when eggs were injected in the AM than in the AC. At 3 wk
posthatch, the MG DNA and IgM percentages for birds in the 1.73 x 104 CFU-AM treatment
group were higher in comparison to the 1.73 x 102 CFU-AM treatment group. Furthermore, those
percentages were higher in the 1.73 x 102 CFU-AM treatment group in comparison to the 173
CFU-AM, 173 CFU-AC, 102 CFU-AC, and 104 CFU-AC treatment groups. The AC groups
regardless of dose and the 173 CFU-AM treatment group were 0.00 % for both MG DNA and
IgM percentages. In addition, the IgG percentages for birds at 3 wk of age was higher in those
injected in the AM rather than in the AC. No birds tested positive for IgG at 3 wk posthatch if
6/85MG was injected into the AC. The MG DNA and subsequent IgM and IgG responses
apparently did not persist until 3 wk posthatch if 6/85MG at any dose was administered via the
AC. Furthermore, MG DNA and IgM were not evident at 3 wk posthatch if the low dose (173
CFU) was administered via the AM. It is well documented that MG mainly colonizes the choanal
cleft and trachea (Cummings and Kleven, 1986; Kleven et al., 1998; Levisohn and Kleven,
2000). At 3 wk posthatch, ELISA results were only detected in chicks that received 6/85MG in
ovo at the 102 and 104 dosages in the AM (Table 3.5). The in ovo vaccination of the Marek’s
disease vaccine has likewise been shown to be effective only when injected in the AM, but not in
the AC (Wakenell et al., 2002; Williams and Hopkins, 2011). In this current study, it is
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confirmed that regardless of dosage, the MG DNA levels and serological responses remained
negative when 6/85MG was injected in the AC.
In conclusion, effects of the in ovo-injection of 6/85MG in the AM and AC on HI, hatch
residue, posthatch performance, and bird serology were determined. The 6/85MG vaccine caused
no hatched chick mortality when injected into the AM at a dosage of 102 CFU, which is similar
to that for the FMG vaccine (Elliott et al., 2017). However, unlike the FMG vaccine, the 6/85MG
vaccine caused no total mortality through d 21 posthatch when injected in the AM at a 173 or 102
CFU dosage. In addition, a live 6/85MG vaccine injected in the AM at the 173, 102, or 104 CFU
dosage level did not result in changes in BW or BWG through d 21 posthatch in comparison to
non-injected controls, whereas in the study by Elliott et al. (2017), FMG at the same dosage
resulted in significant depressions in posthatch BW and BWG in comparison to control
treatments. Our findings revealed that a 104 CFU dosage level of 6/85MG resulted in greater
embryo and early-posthatch mortalities when injected in the AM, whereas the other treatment
groups tested had no adverse effect. Furthermore, the AM site of injection was found to be more
effective compared to the AC. This was confirmed by the MG DNA, IgM, and IgG results when
6/85MG was injected at 18 doi. When the injected in the AM, the 102 and 104 CFU treatment
groups exhibited a humoral response at 3 wk posthatch. However, when injected in the AM, the
104 CFU treatment caused a higher hatched chick mortality when compared to the other
treatment groups. These results indicate that the 1.73 x 102 CFU treatment injected in the AM
would be the best candidate for pragmatic commercial application, in that it did not lead to
embryo and posthatch chick mortalities, but at the same time elicited a humoral response. Further
study is needed to determine the effects of the in ovo injection of different doses of 6/85MG on
hatchability, bird performance, and humoral immune response. Also, an MG field challenge
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study is needed to further evaluate the effectiveness of an in ovo 6/85MG vaccination and its
capability to provide protection against field strain MG infections in the pre-lay and lay periods
of commercial flocks.
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Table 3.1

Mean colony forming units (CFU) of 6/85 Mycoplasma gallisepticum for each 50
μl solution volume administered by in ovo injection to layer embryos at 18 days
(d) of incubation (doi)
Treatment1,2

Dose (CFU)

1 x 10-6

173

1 x 10-4

1.73 x 102

1 x 10-2

1.73 x 104

1

6/85 Mycoplasma gallisepticum was plated from the original vaccine vial on 2 plates. The count was
determined on a 10-4 dilution of the vaccine.
2
Treatments of live 6/85 Mycoplasma gallisepticum vaccine were diluted in Marek’s disease diluent. The
vaccine [1,000 CFU dose vial (NOBILIS® MG 6/85)] was resuspended in a 50 mL diluent and applied as
10-6, 10-4, and 10-2 dilutions, respectively.
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Table 3.2

Main and interaction effect means and P values due to 6/85MG dosage and site of
injection [air cell (AC) or amnion (AM)] for percentage egg weight loss (PEWL)
between 0-12, 12-18, and 0-18 days (d) of incubation (doi); hatchability of injected
eggs containing viable embryos (HI); and mean hatchling BW

1

PEWL
PEWL
PEWL
HI8
7
0-12 d
12-18 d
0-18 d
---------------------(%)--------------------

Hatchling BW9
(g)

Dosage

173 CFU2
1.73 x 102 CFU3
1.73 x 104 CFU4
Pooled SEM
Main effect P-value
Site of Injection5
AC
AM
Pooled SEM
Main effect P-value
Dosage-Site of Injection6
173 CFU-AC
1.73 x 102 CFU-AC
1.73 x 104 CFU-AC
173 CFU-AM
1.73 x 102 CFU-AM
1.73 x 104 CFU-AM
Pooled SEM
Interaction P-value

7.24
7.23
7.29
0.070
0.671

4.11
4.10
4.14
0.056
0.741

11.34
11.35
11.43
0.127
0.723

92.41
95.14
88.84
2.030
0.014

34.78
34.74
34.79
0.277
0.978

7.28
7.23
0.064
0.427

4.12
4.12
0.049
0.944

11.38
11.37
0.105
0.908

94.31
89.94
1.677
0.014

34.67
34.87
0.222
0.372

7.35
7.19
7.31
7.14
7.28
7.28
0.109
0.171

4.13
4.05
4.18
4.09
4.16
4.12
0.084
0.296

11.46
11.25
11.44
11.23
11.45
11.43
0.181
0.252

92.67a
95.38a
94.9a
92.15a
94.9a
82.78b
2.871
0.009

34.64
34.68
34.69
34.92
34.80
34.90
0.375
0.961

a,b

Different letters denote significant difference within a column at P ≤ 0.05.
Main effect means based on 30 eggs in each of 8 trays in each treatment group (240 eggs). Embryonated
eggs were injected in the AM or AC with a 50 μl volume at 18 doi using Embrex machine.
2
173 Colony Forming Unit (CFU) of 6/85 MG was 10-6 dilution from resuspended vial of vaccine, per 50
μl volume.
3
1.73 x 102 CFU of 6/85 MG was 10-4 dilution from resuspended vial of vaccine, per 50 μl volume.
4
1.73 x 104 CFU of 6/85 MG was 10-2 dilution from resuspended vial of vaccine, per 50 μl volume.
5
Main effect means based on 30 eggs in each of 8 trays in each treatment group. All embryonated eggs
were injected at the air cell site on d 18 of incubation. All embryonated eggs were injected at the AM site
on d 18 of incubation.
6
Interaction effect means based on 30 eggs in each of 8 replicate trays in each dosage-site of injection
treatment combination group (240 eggs).
7
Percentage of egg weight loss was calculated based on the difference from initial and final weight of 8
flat replicate started with 30 eggs/flat for each period (0-12), (12-18), and (0-18) doi.
8
Average percentage of embryos that hatched successfully and were alive at pull time when eggs were
injected 18 doi.
9
Hatchling BW was calculated from 8 basket replicates that had approximately 25 chicks each replicate
each treatment.
1
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Table 3.3

Main and interaction effect means and P values due to 6/85MG dosage and site of
injection [air cell (AC) or amnion (AM)] for post-injection pre-pipped and pipped
embryonic mortalities, and hatched chick mortality at pull time [22 days (d) of
incubation (doi)]
Pre-pipped
Pipped embryo
Hatched chick
embryo mortality4
mortality5
mortality6
--------------------------------(%)------------------------------

Dosage1
173 CFU
1.73 x 102 CFU

3.12
1.14

4.63
3.57

0.00
0.00

1.73 x 104 CFU
Pooled SEM
Main effect P-value

4.13
1.221
0.058

3.02
1.594
0.729

3.66
1.102
0.002

1.668b
3.921a
1.009
0.032

3.57
3.910
1.294
0.797

0.158
2.283
0.899
0.024

2.63
0.95
1.43
3.61
1.32
6.83
1.727
0.097

3.74
3.64
3.34
5.53
3.50
2.70
2.214
0.729

0.00b
0.00b
0.00b
0.00b
0.00b
6.85a
1.559
0.008

Site of Injection2
AC
AM
Pooled SEM
Main effect P-value
Dosage-Site of Injection3
173 CFU-AC
1.73 x 102 CFU-AC
1.73 x 104 CFU-AC
173 CFU-AM
1.73 x 102 CFU-AM
1.73 x 104 CFU-AM
Pooled SEM
Interaction P-value
a,b

Different letters denote significant difference within a column at P ≤ 0.05.
Main effect means based on 30 eggs in each of 8 trays in each treatment group (240 eggs). Embryonated
eggs were injected in the AM or AC with a 50 μl volume at18 doi using Embrex machine.
2
Main effect means based on 30 eggs in each of 8 trays in each treatment group. All embryonated eggs
were injected at the air cell site on 18 doi. All embryonated eggs were injected at the AM site on 18 doi.
3
Interaction effect means based on 30 eggs in each of 8 replicate trays in each dosage-site of injection
treatment combination group (240 eggs).
4
Embryos externally pipped eggshell but did not fully hatch.
5
Embryos that had died and did not externally pip the eggshell at pull time (at 22 doi).
6
Full hatched chicks that were found dead in the hatch basket at pull time.
1
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Table 3.4

Main and interaction effect means and P values due to 6/85MG dosage and site of injection [air cell (AC) or amnion
(AM)] for BW at 0, 7, 14, and 21 days (d) posthatch; BW gain (BWG) between 0 and 7 (BWG7), 7 and 14 (BWG14),
14 and 21 (BWG21) and 0 and 21 (BWG0-21) d posthatch; and total chick mortality through d 12 posthatch
BW04

BW7

BWG7

BW14

BWG14

BW21

BWG21

BWG0-21

-----------------------------------------------(g)-----------------------------------------------1

Total
mortality5
(%)

Dosage

173 CFU

34.59

63.94

29.35

114.84

50.90

180.64

65.80

146.06

0.00

1.73 x 102 CFU

34.88

58.70

23.85

110.00

51.30

183.55

70.78

148.66

0.00

1.73 x 104 CFU

34.80

60.78

23.88

113.25

55.81

173.63

60.36

136.70

20.83

Pooled SEM

0.364

4.235

3.400

2.451

4.616

6.913

5.569

6.882

7.079

0.719

0.475

0.204

0.161

0.510

0.358

0.202

0.216

0.012

AC

34.63

61.59

26.98

111.43

49.82

173.92

62.48

139.28

0.00

AM

34.88

60.68

24.40

113.97

55.53

184.62

68.82

148.34

13.88

Pooled SEM

0.297

3.458

2.773

2.001

3.769

5.645

4.547

5.620

5.781

0.396

0.796

0.364

0.220

0.147

0.074

0.180

0.124

0.027

173 CFU-AC

34.23

63.43

29.20

112.00

48.57

173.78

61.75

139.55

0.00b

1.73 x 102 CFU-AC

35.00

59.70

24.70

109.18

49.45

177.60

68.40

142.55

0.00b

1.73 x 104 CFU-AC

34.65

61.65

27.05

113.10

51.43

170.38

57.28

135.73

0.00b

Main effect Pvalue
Site of Injection2

Main effect Pvalue
Dosage-Site of
Injection3
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Table 3.4 (continued)
BW0

4

BW7

BWG7

BW14

BWG14

BW21

BWG21

BWG0-21

Total
mortality5
(%)

--------------------------------------------------(g)-----------------------------------------------173 CFU-AM

34.95

64.45

29.20

117.67

53.23

187.50

69.57

152.57

0.00b

1.73 x 102 CFU-AM

34.75

57.70

23.00

110.83

53.15

189.50

73.15

154.78

0.00b

1.73 x 104 CFU-AM

34.95

59.90

20.70

113.40

60.20

176.88

63.45

137.68

41.65a

Pooled SEM

0.515

5.989

4.803

3.467

6.528

9.777

7.876

9.733

10.012

Interaction P-value

0.424

0.925

0.612

0.534

0.844

0.864

0.956

0.674

0.012

a,b

Different letters denote significant difference within a column at P ≤ 0.05.
Main effect means based on 6 birds in each of 4 cages in each treatment group (24 birds). Embryonated eggs were injected in the amnion or air
cell with a 50 μl volume at 18 doi using Embrex machine.
2
Main effect means based on 6 birds in each of 4 cages in each treatment group. All embryonated eggs were injected at the air cell site on d 18 of
incubation. All embryonated eggs were injected at the amnion site on 18 doi.
3
Interaction effect means based on 6 birds in each of 4 replicate cages in each dosage-site of injection treatment combination group (24 birds).
4
BW0 (g) is average chick BW at pull time; BW7 is average chick BW at 7 d of age; BWG7 is average BWG from 0 to 7 d; average chick BW at
14 d; BWG from 7 to 14 d; average chick BW at 21 d; BWG from 14 to 21 d; BWG from 0 to 21 d. All variables were calculated based on 6 birds
in 4 replicate cages in each treatment.
4
Total mortality of 6 chicks placed into 4 cages (n=24) for each treatment in the first 12 d of age.
1
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Table 3.5 Main and interaction effect means and P values due to 6/85MG dosage and site of injection [air cell (AC) or amnion
(AM)] for percentage of birds that tested positive for MG DNA in the choanal cleft at 22 days (d) of incubation (doi)
(Hatch DNA) and at 3 weeks (wk) posthatch (3 wk DNA); and IgM (3 wk IgM) and IgG (3 wk IgG) serologic responses
in the serum at 3 wk posthatch
Hatch DNA4

Dosage1
173 CFU
1.73 x 102 CFU
1.73 x 104 CFU
Pooled SEM
Main effect P-value
Site of Injection2
AC
AM
Pooled SEM
Main effect P-value
Dosage-Site of Injection3
173 CFU-AC
1.73 x 102 CFU-AC
1.73 x 104 CFU-AC
173 CFU-AM
1.73 x 102 CFU-AM
1.73 x 104 CFU-AM

3 wk DNA5

3 wk IgM6

3 wk IgG7

-------------------------(%)-------------------------

(mg/dL)

18.75c
43.75b
62.50a
14.430
0.015

0.00
23.91
39.29
5.590
≤ 0.0001

0.00
32.61
42.86
5.177
≤ 0.0001

105.92
108.39
169.11
29.870
0.068

16.67b
66.67a
11.785
≤ 0.0001

0.00
42.13
4.466
≤ 0.0001

0.00
50.31
4.132
≤ 0.0001

0.00b
255.61a
23.730
≤ 0.0001

0.00
12.50
37.50
37.50
75.00
87.50

0.00c
0.00c
0.00c
0.00c
47.83b
78.57a

0.00c
0.00c
0.00c
0.00c
65.22b
85.71a

0.00
0.00
0.00
211.83
216.78
338.21
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Table 3.5 (continued)
Hatch DNA4

3 wk DNA5

3 wk IgM6

-------------------------(%)-------------------------

3 wk IgG7
(mg/dL)

Pooled SEM

20.412

7.288

6.744

38.735

Interaction P-value

0.689

≤ 0.0001

≤ 0.0001

0.068

a,b

Different letters denote significant difference within a column at P ≤ 0.05.
Main effect means based on 6 birds in each of 4 cages in each treatment group (24 birds). Embryonated eggs were injected in the AM or AC with
a 50 μl volume at 18 doi using Embrex machine. Diluent is a control treatment embryo that injected with 50 μl of Marek’s Diluent.
2
Main effect means based on 6 birds in each of 4 cages in each treatment group. All embryonated eggs were injected at the air cell site on 18 doi.
All embryonated eggs were injected at the AM site on 18 doi.
3
Interaction effect means based on 6 birds in each of 4 replicate cages in each dosage-site of injection treatment combination group (24 birds).
4
Birds were swabbed at hatch in choanal cleft for 6/85 Mycoplasma gallisepticum DNA detection via PCR: one chick per replicate flats (N= 8) for
each treatment.
5
Birds were swabbed at 3 wk of age in choanal cleft for Mycoplasma gallisepticum DNA detection via PCR: 6 chicks per replicate cages (N= 4)
for each treatment except high dose AM treatment (14 chicks total) due to chick mortality.
6
Birds were bled at 3 wk of age after swab for serum plate agglutination (SPA) to test for IgM antibodies against Mycoplasma gallisepticum: 6
chicks per replicate cage (N= 4) for each treatment, except for the high dose AM treatment (14 chicks total) due to chick mortality.
7
Blood samples also analyzed at 3 wk of age by ELISA to test for IgG antibodies against Mycoplasma gallisepticum: 6 chicks per replicate cage
(N= 4) for each treatment, except for the high dose AM treatment (14 chicks total) due to chick mortality. Non-injected and injected diluent AM,
diluent air cell, low air cell, medium air cell, and high air cell treatments were not tested for ELISA due to negative DNA and SPA results.
Treatment means within the same column with differing superscripts are significantly different (P < 0.05).
1
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Figure 3.1

Hy-Line W-36 layer chicks exhibiting twisted and extended necks upon receiving the high
dose (104 CFU) of 6/85MG in the AM at 18 days of incubation. Chicks in all other
treatment groups, including controls and the lower 6/85MG treatment doses, did not
exhibit this behavior.
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CHAPTER IV
TRANSMISSION AND IMPACT OF AN IN OVO-APPLIED TEMPERATURE-SENSITIVE
MYCOPLASMA GALLISEPTICUM LIVE VACCINE IN LAYER EMBRYOS AND
POSTHATCH CHICKS
4.1

Abstract
Mycoplasma gallisepticum (MG) contributes to chronic respiratory disease in chickens

and is prevalent in commercial layer flocks. Effects of the in ovo injection of the ts-11MG
vaccine (ts-11MGV) on the transmissibility of ts-11MGV between incubated eggs and chicks
and the subsequent posthatch performance of the chicks were evaluated. Five treatments each
consisting of 30 eggs were randomly distributed on each of 12 replicate levels in a single-stage
incubator. The ts-11MGV was manually in ovo-injected into the amnion on 18 days (d) of
incubation (doi). Embryos were injected with commercial Marek’s disease diluent (controls), or
diluent containing either 7.25 x 102, 103, 104, or 105 CFU of ts-11MGV. Diluent-injected control
eggs were designated as either unexposed (UC) or exposed (EC) controls and assigned to
separate identical incubators. The UC eggs were incubated alone on a single tray level, and the
EC eggs were incubated with ts-11 MGV eggs for detection of possible horizontal transmission
within the incubator. Egg residue analysis, hatchability of injected eggs containing viable
embryos (HI), and embryonic mortality were assessed by statistical analysis for the EC, and the
7.25 x 102, 103, 104, and 105 CFU treatment groups. Twelve hatchlings per treatment were
swabbed in the choanal cleft for the detection of MG DNA via PCR. Posthatch variables
82

including hatchling body weight (BW), were assessed by statistical analysis for the EC, and the
7.25 x 103, 104, and 105 CFU treatment groups. The UC treatment was also included in the
posthatch period, but was not included in the statistical analysis. Three replicate biological
isolation units were assigned to each of the 5 posthatch treatment groups. Within each unit, 20
female chicks were placed. To assess possible posthatch horizontal transmission, 5 male sentinel
chicks derived from the UC treatment were also allocated to each biological isolation unit. Birds
were reared to 3 weeks (wk) of age for early posthatch evaluation. Mean female chick BW in
each unit was determined at 0 (after placement) and 21 d posthatch, and BW gain between 0 and
21 d posthatch (BWG21) was subsequently calculated. Birds were swabbed for MG DNA
detection and bled for IgM and possible IgG production at 21 d posthatch. There were no
significant treatment differences for the hatch variables or serum IgM levels at 3 wk posthatch.
Only bird BWG21 (P = 0.023) in the 7.25 x 105 ts-11 MGV treatment was significantly lower in
comparison to all the other treatment groups. No MG DNA was detected in any of the birds in
the hatch and posthatch periods. These results showed that the ts-11MGV was not transmitted to
the tissues of birds that received the vaccine by in ovo injection, and was not horizontally
transmitted during the late incubation and grow out phases. It is possible that the incubation
temperature (37.5°C) rendered the temperature sensitive ts-11MGV ineffective. These results
indicate that ts-11MGV does not exhibit vertical or horizontal transmission capabilities under
commercial conditions and may, therefore, not be a good candidate for in ovo injection.
Key words: Transmission, layer embryo, in ovo, Mycoplasma gallisepticum, ts-11-strain
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4.2

Introduction
Mycoplasma gallisepticum (MG) is highly pathogenic and causes infections in poultry

worldwide that results in significant economic losses in commercial poultry operations
(Carpenter et al., 1981; Mohammed et al., 1987; Stipkovits and Kempf, 1996; Levisohn and
Kleven, 2000). An MG infection causes avian respiratory mycoplasmosis, which can lead to
chronic respiratory disease in chickens and infectious sinusitis of turkeys, with subsequent
increases in mortality and reduced growth rates (Stipkovits and Kempf, 1996; Levisohn and
Kleven, 2000). It is well known that field strain MG infections reduce table egg production in
commercial egg-laying hens (Kleven et al., 1990; Ley and Yoder, 1997; Kleven, 1998; Kleven et
al., 1998; Levisohn & Kleven, 2000). Carpenter et al. (1981) and Evans and Hafez (1992) have
verified egg production losses in MG-infected layer chickens when compared to MG-free hens.
In addition to a loss in egg production, egg quality can also deteriorate in hens infected with MG
(Pruthi & Karole, 1981; Stipkovits and Kempf, 1996; Levisohn and Kleven, 2000). The live
attenuated ts-11 strain of MG (ts-11MG) vaccine (ts-11MGV) licensed by USDA is currently
administered by eye-drop during the pullet phase and has been proven to be avirulent in
chickens.
Horizontal transmission of MG occurs through either direct or indirect contact with
respiratory fluids, and hens can also transmit the infection vertically in ovo (Ley, 2008).
Nevertheless, controlling MG infection via vaccines has been effective when isolation and
biosecurity measures are impossible to achieve (Whithear, 1996; Kleven, 1997; Levisohn and
Kleven, 2000). Though the frequency of MG infection has been drastically reduced over the last
50 years through eradication and isolation, it remains a current commercial concern (Ley, 2008).
Live vaccines can also be used to compete with and displace wild-type MG strains in poultry
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flocks (Levisohn and Kleven, 1981; Kleven et al., 1998; Turner and Kleven, 1998). Globally, the
commercial poultry industry currently uses both live and killed vaccines to control infection
(Whithear et al., 1996). All 3 of the MG vaccine strains [F strain of MG (FMG), 6/85 strain of
MG (6/85MG), and ts-11MG have different features that can be useful in determining how to
effectively control and eradicate field strains of MG. Depending on the type of infection being
addressed, one vaccine strain might be found to be more effective than another. These features
include protection (Abd-El-Motelib and Kleven, 1993), transmission (Ley et al., 1997),
pathogenicity (Evans and Hafez, 1992; Whithear et al., 1990), and the ability to displace field
strains (Kleven et al., 1990). The FMG vaccine in particular is known to create higher levels of
protection (Abd-El-Motelib and Kleven, 1993) as well as displacing the Rlow-strain of MG
(RMG) (Kleven et al., 1998). However, it has the potential to spread horizontally within a flock
(Ley et al., 1997).
A series of studies were previously conducted to evaluate effects of the in ovo injection
of FMG at 18 d of incubation (doi) on layer chick hatchability (Elliott et al., 2017), posthatch
survivability and immunity (Elliott et al., 2018), and possible posthatch horizontal transmission
(Elliott et al., 2019). Different doses (2.4 to 2.4 x 106 CFU) of the inoculum were tested. After
administration of all doses tested, FMG was detected in the trachea, mouth, esophagus, yolk sac,
and lumen of the duodenal loop at 22 doi (Elliott et al., 2017). In a subsequent study by Elliott et
al. (2018), it was reported that in ovo injection of the lowest dose (2.4 CFU) had the least impact
on livability and BW, but exhibited the lowest humoral immune response. In addition, Elliott et
al. (2018) observed that the posthatch BW of the birds belonging to the 2.4 x 102, 104, and 106
CFU FMG in ovo treatment groups was significantly lower compared to those given the lower
dosages and to those in a diluent-injected control group. Furthermore, when FMG was applied in
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ovo at 18 doi, it was subsequently transmitted from vaccinated to unvaccinated birds when they
were in direct contact (Elliott et al., 2019).
Although, the FMG vaccine provides more protection from field-strain MG infections, it
is more virulent in comparison to the 6/85MG and ts-11MG vaccines. The 6/85MG and ts-11MG
vaccine strains may be less effective, but are considered safer to use, as they are both
apathogenic strains (Whithear et al., 1990; Evans and Hafez, 1992; Abd-El-Motelib and Kleven,
1993; Kleven et al., 1998). These differences are important to consider when attempting to
formulate a plan for addressing the protection of a flock against field strain MG infections. The
objective of this study was to examine the transmissibility of ts-11MG during incubation and
posthatch periods and its subsequent effects on various hatch variables and serologic responses,
when applied by in ovo injection to layer embryos.
4.3
4.3.1

Materials and Methods
Egg Incubation
A total of 2,160 fertile Hy-Line W-36 layer eggs, were obtained from a 40 wk-old MG-

clean commercial breeder flock (Hy-Line Company, Mansfield, GA). Eggs were incubated in
calibrated single stage NMC2000 NatureForm Incubators (NatureForm Incubator Company,
Jacksonville, Florida). Unexposed diluent-injected control eggs (UC) were incubated on one tray
level in a separate incubator (designated as UC incubator) from the ts-11MGV-injected eggs in
order to prevent possible ts-11MG cross-contamination. The UC eggs were used for
observational (non-statistical) comparison purposes for the base line values of eggs that had no
potential exposure to the ts-11MGV during incubation. In the other incubator, eggs that were
injected with diluent alone or with diluent containing one of 4 levels of the ts-11MGV were
incubated on 12 tray levels. The diluent-injected control eggs (EC) in that incubator were set in
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the same incubator (designated as ts-11MGV incubator) with the ts-11MGV treatment groups for
the examination of possible ts-11MG transmission between vaccinated and unvaccinated eggs.
Both incubators were located in the same room and were set at the same temperature and
humidity [37.50 °C dry bulb and 29.44 °C wet bulb (55 % relative humidity) (RH)] for the first
18 days (d) of incubation (doi). The RH remained the same (28.75 °C wet bulb), but the
temperature of both incubators was reduced to a 36.7 ◦C dry bulb temperature for the last 4 doi.
Three HOBO temperature/RH data loggers (Onset Computer Corporation, Bourne, MA) were
placed in the top, middle, and bottom tray levels of the ts-11MGV incubator to accurately record
environmental conditions. One HOBO logger was placed on the one tray level in the UC
incubator. Logger readings were recorded every 15 minutes during both the setter and hatcher
incubational phases.
4.3.2

Treatment Designation and Application
The ts-11MGV (VaxSafe MG Vaccine, TS-11) was resuspended in Marek’s disease

diluent to achieve 4 concentrations in 10 x increments. The 1x10-5 dilution of the ts-11MGV was
prepared on the same d of injection by diluting the ts-11MGV in diluent so that 72.5 CFU of the
organism was present in each 50 μL volume of solution that was injected into each egg. In
addition, the 1 x 10-4, 1 x 10-3, 1 x 10-2, and 1 x 10-1 dilutions, respectively, contained 7.25 x 102,
103, 104 and 105 CFU of the organism in each 50 μL volume of solution that was injected into the
amnion (AM) of each egg (Table 4.1). Groups of 30 eggs belonging to each of 5 treatment
groups (EC, and 4 ts-11MGV dosage groups) were randomly arranged on 12 replicate tray levels
of the ts-11MGV incubator. At 12 doi, infertile eggs and those containing dead embryos were
removed, and only those eggs containing viable embryos were vaccinated at 18 doi. At 18 doi,
all live embryonated eggs in each replicate treatment group received manual amniotic injections
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of ts-11MGV following the procedures of Embrex, Inc. (2002) and later used in an earlier
experiment by Elliott et al. (2017). All injections were performed by the same individual to
increase the consistency of injection methodology between eggs. Before injection, the ts-11MGV
was plated on Frey’s Mycoplasma agar (Frey et al., 1968) and incubated at 32 °C to confirm
vaccine viability and the actual dosage being delivered. The amniotic treatments included diluent
only-injected controls (UC and EC) [Poulvac Marek’s disease diluent (Zoetis, Parsippany, NJ)],
and diluent containing either 7.25 x 102, 103, 104, or 105 CFU/dose of ts11MGV.
Localization of injections were verified by injecting dye into one embryonated egg from
each of the 5 treatment groups on each of the 12 replicate tray levels in the ts-11MGV incubator
and the one tray level in the UC incubator (12 eggs per treatment; 72 total eggs). The eggs were
injected with Coomassie brilliant blue R-250 dye (Genlantis, San Diego, CA) and opened to
locate the site of injection including the AM, body proper, and yolk sac, and the stage of
embryonic development using the Embrex embryo stage scoring procedure developed by Zoetis
(Avakian, 2006) and further employed by Sokale et al. (2017). After injection of the live
embryonated eggs from each treatment replicate group, they were randomly allocated to 6
sections within each of 2 hatching baskets on each of 5 tray levels (one treatment per level) for
the hatching phase in the ts-11MGV incubator that coincided with the treatment replicate groups
represented in the setter phase. Hatching baskets containing eggs that received the high (7.25 x
105 CFU) ts-11MGV dosage were placed at the bottom of the hatcher, and the lower doses (7.25
x 102, 103, and 104 CFU, in that consecutive order, beginning at the top portion of the hatcher)
treatment groups were placed so as to eliminate cross-contamination via chick droppings. In the
UC incubator, after injection of embryonated eggs, UC eggs were allocated to 6 sections within
each of 2 hatching baskets on one tray level. The incubator and data loggers in both incubators
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were monitored daily to ensure their proper function and that the eggs were incubated under
optimum conditions.
4.3.3

Sampling at Hatch
Egg residues were marked, counted, and subsequently opened for embryonic

development stage confirmation (Mauldin and Wilson, 2014). Percentages of hatchability of
injected live embryonated eggs (HI), and pre-pipped embryo, pipped embryo, and hatched chick
mortalities were determined at 22 doi. Bird husbandry, handling, sampling, and euthanasia
procedures were approved by a USDA-ARS Animal Care and Use Committee (Mississippi State,
MS). In each of the 6 treatment groups on each of the replicate tray levels, mean straight run
hatchling body weight (BW) was determined, and one chick was randomly selected for
additional analysis. Each chick (72 total chicks) was weighed, euthanized, and their choanal
clefts were immediately swabbed for MG DNA analysis. Birds in the UC and EC, and 7.25 x
102, 103, 104, and 105 CFU dosage treatment groups were swabbed in that order.
4.3.4

Posthatch Bird Raising and Sampling
Hatched chicks were counted and weighed and only females were used in the posthatch

phase of the study. Female chicks from each replicate tray level that belonged to either the UC,
EC, 7.25 x 103 CFU, 7.25 x 104 CFU, or 7.25 x 105 CFU treatment were pooled (approximately
300 birds). Twenty chicks from each of the 5 treatment groups were randomly assigned to each
of 3 biological isolated units (BIU) that occupied a common room, and were raised to 3 wk of
age. Each BIU measured 1.42 m x 0.65 m (0.92 m2). Stocking density was 0.04 m2 per bird to
meet Hy-Line W-36 breeder pullet recommendations (Hy-Line Red Book, Hy-Line International,
2014). To assess possible posthatch horizontal transmission, 5 male sentinel chicks derived from
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the UC treatment were also allocated to each BIU. Due to space limitations, the lowest dosage
treatment (7.25 x 102 CFU) was not maintained beyond hatch. The birds belonging to that
treatment group were weighed before being humanely euthanized. It was reasoned that this
lowest dosage treatment group could be practically eliminated, as its hatch results were not
statistically different from the other treatments.
Each BIU had a bell drinker and a circular gravity-fed feeder that would accommodate up
to 10-12 birds simultaneously. A flat feed tray was provided for the first wk posthatch before the
feeder was used. All birds had ad libitum to water and feed during the entire grow-out period.
The pullets were fed a crumble starter diet that met the recommended NRC requirements (NRC,
1994). According to Hy-Line recommendations for W-36 pullets, the lighting program provided
21 h of light and 3 h of dark in the room during the first wk, and 20 h of light and 4 h of dark
until d 21 of age. Furthermore, as recommended, room air temperature was 34◦C on the first d
and was lowered by 2 to 3 ◦C daily until 21 ◦C was reached. Birds belonging to the UC and then
the EC control treatments were monitored daily before those belonging to the ts-11MGV
treatments, in order to prevent possible cross-contamination. Birds in the 7.25 x 103, 104, and 105
CFU treatment groups were likewise monitored daily, in that respective order, to further prevent
possible cross-contamination. Chick mortality was monitored daily with dead chicks being
weighed on a daily basis. After chick placement in each replicate BIU, mean female chick BW
was determined on Day 0 (BW0) and on d 21 (BW21) posthatch. The difference between mean
BW0 and BW21 was used to calculated mean 0 to 21 d BW gain (BWG21) for each replicate
BIU.
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4.3.5

Choanal Cleft Swabbing
Pre-wetted sterile swabs in phosphate-buffered saline were used to swab the choanal cleft

of the birds at hatch and at 3 wk posthatch for ts-11MG detection. All swabs were suspended in
100 μL of phosphate-buffered saline and extracted using a BioSprint 96 One-For-All Kit
(Qiagen, Valencia, CA). All swab samples were run in duplicate using a 7500 Fast Real Time
PCR System (Applied Biosystems, Foster City, CA). A specific MG primer and probe were used
for DNA analysis. A 25 μL sample volume was used for PCR testing, which included 2.5 μL of
forward primer, 2.5 μL of probe, 12.5 μL of Taqman Universal Master Mix (Applied
Biosystems, Foster City, CA), and 2.5 μL of extracted DNA in sterile water (Raviv et al., 2008).
A 22.5 μL volume of master mix was loaded into each well of a 96-well-plate, and 2.5 μL of
sample DNA was then subsequently added to each well. Each plate included a negative control
that contained sterile water only, and a positive control containing RMG to design a standard
curve including 10-1, 10-2, and 10-3 dilutions. The protocol by Nascimento et al. (1991) was used
for ts-11MG detection by PCR. The qPCR cycling process used was as described by Raviv et al.
(2008).
4.3.6

Blood Sampling and Immunology
After the birds were swabbed at 3 wk of age, they were immediately bled and

approximately 3 mL of blood from each bird was collected and kept at room temperature for 2 h.
After clotting, sera were centrifuged and poured into labelled vials and stored at 4°C until use.
For detection of IgM antibodies against MG, SPA analysis was conducted, and only SPApositive samples were further analyzed by ELISA for the presence of IgG antibodies against
MG. For SPA analysis, one drop of MG antigen was added to each individual 30 μL volume of
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serum. The mixes were shaken on a Clinical Rotator (Fisher Scientific, Hampton, NH) for 3 to 5
min.
4.4

Statistical Analysis
A randomized complete block design was employed for the hatch results, which included

HI, egg residue analyses, and hatchling BW, where incubator tray level was considered as the
blocking factor. All treatments were randomly assigned to each block (tray level). Those
treatments housed in the same incubator were compared statistically. The UC control treatment
was not analyzed with the EC control and ts-11MGV treatments, and only used for numeric
comparison. Posthatch BW0, BW21, and BWG21; MG DNA detection by qPCR; and MG
antibodies detected by SPA and ELISA tests were analyzed using a completely randomized
experimental design, where replicate BIU was the experimental unit. All data were analyzed by
one-way ANOVA of SAS 9.4 (SAS Institute, 2014) employing PROC MIXED, and means
separations were performed using Fisher’s protected least significant difference in the event of
significant global effects. Statements of significance were based on P ≤ 0.05 unless otherwise
stated.
4.5
4.5.1

Results and Discussion
Prehatch, Hatch, and Posthatch Variables of the Unexposed Diluent-Injected
Control (UC) Treatment
The UC treatment group alone occupied a separate hatcher, and was, therefore, not

compared statistically with the other treatment groups. The swab samples from the UC treatment
possessed no MG DNA at hatch or at d 21 posthatch, and all UC birds tested SPA negative for
IgM on d 21 posthatch. In the UC treatment, mean 0-12 PEWL, 12-18 PEWL, 0-18 PEWL, HI,
hatchling BW, and pre-pipped embryo, pipped embryo, and hatched chick mortalities were 7.23
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%, 3.92 %, 11.15 %, 96.63 %, 40.32 g, 0.98 %, 0.32 %, and 0.99 % respectively. The PEWL; HI;
hatchling BW; pre-pipped embryo, pipped embryo, and hatched chick mortalities; and MG DNA
and IgM detection results were comparable to those in the EC treatment group (Tables 4.2. and
4.3.). This suggests that the EC group was solely adequate for statistical control comparison to
the ts-11MGV treatment groups in the prehatch and posthatch phases.
The UC treatment group means for BW0, BW21, and BWG21, were 40.2 g, 192.1 g, and
151.9 g, respectively. These BW0, BW21, and BWG21 results were comparable to those in the
EC group (Table 4.4), which further establishes that the EC treatment is likewise sufficient for
statistical control comparison to the ts-11MGV treatment groups during the posthatch phase. The
birds in the UC treatment group, and the male sentinel birds in each treatment group did not
show any signs of infection, and their swab and blood samples were negative for MG presence
and IgM antibody production at d 21 posthatch. Therefore, birds hatched from eggs in the UC
treatment remained ts-11MG free through 21 d posthatch, and ts-11MGV was not transmitted to
the male UC sentinel birds that were placed in contact with the ts-11MGV birds during the
posthatch phase. Kinney (1993) and Whithear et al. (1990) also observed that after hens were
vaccinated with ts-11MG by eye drop at 22 wk of age, no evidence of ts-11MG was detected in
their eggs or oviducts. It has also been reported that ts-11MG is relatively avirulent and exhibited
no transmission from ts-11MGV vaccinates to unvaccinated sentinel birds that occupied
adjoining pens and had indirect contact with the vaccinates. Furthermore, no birds displayed any
clinical signs of morbidity or mortality, and no gross lesion were observed when necropsied (Ley
et al., 1997).
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4.5.2

Prehatch, Hatch, and Posthatch Variables of the Exposed Diluent-Injected
Control (EC) and Ts-11MGV Treatments
The EC treatment group occupied the same incubator as those injected with the various

ts-11MGV doses, in order to test for ts-11MGV transmission during the incubational period. The
swab and blood samples from the EC and ts-11MGV treatments possessed no MG DNA and
there were no IgM serological responses due to delivery of the ts-11MGV via in ovo injection.
The prehatch and hatch variables in the EC and 4 ts-11MGV treatment groups (7.25 x 102, 7.25 x
103, 7.25 x 104, and 7.25 x 105 CFU) were statistically compared. Mean 0-12 PEWL, 12-18
PEWL, 0-18 PEWL, HI, and hatchling BW were not significantly different between these 5
treatment groups (Table 4.2). In addition, there were no significant differences between the 5
treatment groups for pre-pipped embryo, pipped embryo, and hatched chick mortalities (Table
4.3). These combined results suggest that injection of the ts-11MGV in the AM at 18 doi has no
negative impact on embryo development and subsequent hatch variables. Furthermore, when
incubated in the same incubator, there is no observable horizontal transmission of ts-11MG
between eggs.
The posthatch variables in the EC and 3 ts-11MGV treatment groups (7.25 x 103, 7.25 x
104, and 7.25 x 105 CFU) were statistically compared. There were no posthatch mortalities
recorded between d 1 and 21 posthatch in any of the replicate pens within each treatment group.
There were no significant differences among the EC and 3 ts-11MGV treatment groups for BW0
and BW21 (Table 4.4). However, BWG21 in the 7.25 x 105 CFU treatment group was
significantly (P = 0.023) lower than that in the EC, 7.25 x 103 CFU, and 7.25 x 104 CFU
treatment groups (Table 4.4). Vance et al. (2008) eye-inoculated pullets at 10 wk of posthatch
age with 106 CFU of ts-11MG, and observed no subsequent negative effects on layer BW
between 18 and 57 wk of posthatch age. Apparently, a 106 CFU dosage of the ts-11MGV given
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prelay of 10 wk of age (Vance et al., 2008) causes no physiological consequences in the pullet
period. Furthermore, no previous work has reported that a prelay ts-11MG vaccination regimen
affects hen BW (Burnham et al., 2002; Peebles et al., 2007; Vance et al., 2009). In this study,
doses up through 7.25 x 104 CFU similarly showed no outward clinical indications of negative
physiological impacts on the embryos, including the lack of subsequent effects on BW or BWG.
There were also no observed posthatch bird mortalities in any of the treatment groups, which is
in agreement with Vance et al. (2008), who showed no adverse impact on mortality when birds
were inoculated with ts-11MG via eye drop at 10 wk of age. Nevertheless, the highest dosage
used in this study (7.25 x 105 CFU) led to a decrease in BWG21, which suggests that when
administered by in ovo injection, ts-11MGV can cause a subsequent negative impact on
posthatch performance, whereas when given to pullets at doses as high as 106 CFU, no adverse
effects on performance are realized.
The results of the current study are, therefore, largely in agreement with these earlier
studies and indicate that whether or not ts-11MG is administered by in ovo injection or later in
the prelay pullet period, that depending on the dosage delivered, bird growth may not necessarily
be adversely affected. Vance et al. (2008) did not report the effect of a prelay ts-11MG
vaccination on layer BWG. However, BWG21 in the 7.25 x 105 CFU treatment group was
significantly lower compared to the other treatment groups in this current study. Layer embryos,
therefore, appear to be more sensitive to ts-11MG than pullets when it is administered at higher
dosages, and that a dosage of 7.25 x 105 CFU or greater can have subsequent adverse effects on
posthatch growth when administered by in ovo injection.
Although ts-11MG DNA and serum serologic responses were not tested, Peebles et al.
(2009) tested the effects of a prelay ts-11MG vaccination (at 10 wk of age) on other blood
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characteristics of hens, and only serum calcium concentrations were increased at 22 wk of age.
In addition, Vance et al. (2009) noted that the relative digestive and reproductive organ weights
of laying hens at 58 wk of age, that were previously inoculated with ts-11MG in the pullet period
(10 wk of age), were not significantly affected. It is possible that the ts-11MG used in earlier
studies did not affect bird performance because no effects were observed in the digestive and
reproductive organ variables examined (Vance et al., 2009), and only serum calcium levels were
elevated (Peebles et al., 2009). These same blood and organ variables were not examined in the
current study, but it is suggested that the 7.25 x 105 CFU dosage may have caused some adverse
effects in some of these variables. Furthermore, the vaccinates may have experienced an
impairment in nutrient utilization. Random physiological effects, such as these, on embryos
subjected to the higher dose (7.25 x 105 CFU) in the current study, may have led to the
significant decrease in BWG21.
In a subsequent study by Elliott et al. (2018), FMG was applied by in ovo injection at 18
doi. It was reported that 2.4 x 104 and 2.4 x 106 CFU doses resulted in more than a 50 %
posthatch chick mortality and caused a significant reduction in BW. In addition, Elliott et al.
(2018) observed that the posthatch BW of birds belonging to the 2.4 x 102, 104, and 106 CFU
FMG in ovo treatment groups were significantly lower compared to those given lower dosages
and to those in a diluent-injected control group. Only the very lowest dosage of FMG (2.4 CFU)
allowed for a 95.2 % hatchability and normal posthatch growth, whereas in the current study, up
to 7.25 x 105 CFU dosage showed no negative impact. It appears that up to 7.25 x 105 CFU
dosage is tolerated when ts-11MGV rather than FMG is used for in ovo injection, due to the
lower virulence level of the ts-11MG. Furthermore, when FMG was applied in ovo at 18 doi, it
was successfully transmitted from vaccinated to clean sentinel chicks when they were in direct
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contact (Elliott et al., 2019). Nevertheless, in this study, no posthatch ts-11MG transmission
occurred between vaccinated and clean sentinel birds that occupied the same BIU regardless of
the ts-11MGV dosage used.
The birds in the current study did not show an immune response to the ts-11MGV
treatments imposed. The GapA gene is the primary cytadhesin molecule in MG (Goh et al.,
1998; Keeler et al., 1996), and MG attaches to target cells via cytadhesins where interactions
occur with their corresponding host cells receptors (Geary and Gabridge, 1987; Geary et al.,
1989). The GapA gene is expressed in virulent MG strains as well as in FMG, where it is
important for cytadherence and their subsequent virulence properties (Papazisi et al., 2002).
However, the GapA gene is absent in the ts-11MG vaccine strain (Mudahi-Orenstein et al.,
2003), which may make the ts-11MG vaccine less efficient. Therefore, ts-11MG is relatively
avirulent and exhibits a low potential for transmission to uninfected birds (Ley et al., 1997;
Vance et al., 2008; Levisohn and Kleven, 2000). These noted properties would provide at least a
partial basis for differences in the virulence levels of FMG and ts-11MG and for differences in
the dosage effects reported for the FMG and ts-11MG in ovo vaccines. It has been reported that
ts-11MG is not detected systemically in birds until 2 to 3 wk post vaccination (Whithear, 1996).
This would help explain why ts-11MG was not detected at hatch and had no effects on the hatch
variables examined in the current study. The effects of the highest dosage (7.25 x 105 CFU) of
the in ovo ts-11MGV on BWG21 in the posthatch phase likely occurred because the ts-11MG
was allowed more time to colonize in the birds.
In conclusion, the in ovo injection of ts-11MGV at 18 doi had no negative impact on the
HI and posthatch immunity of layers. However, it is possible that physiological (organ and
blood) variables that were not investigated in this study may have played a role in the negative
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effects that in ovo ts-11MGV had on BWG21. Although ts-11MG is relatively avirulent in
comparison to other vaccine strains of MG such as FMG, the embryo appears to be more
sensitive to ts-11MG when applied in ovo rather than as an eye drop in the pullet phase. This was
evidenced by the decrease in BWG21 in the group that received the highest dosage. This effect
may be due to the fact that the ts-11MGV requires a longer time for systemic colonization due to
its low level of virulence. The ts-11MG was not transmitted from vaccinated to sentinel birds at
both the hatch and posthatch periods and no subsequent MG DNA or serology responses were
detected. This may result in a weak vaccination consistency among all birds in a flock when ts11MG is applied in ovo. Because transmission of an MG vaccine between birds in a flock is
important for total flock protection, this is a matter of concern for the in ovo use of ts-11MGV.
Therefore, ts-11MG may not be a good candidate for in ovo injection for subsequent protection
of commercial layer flocks against field-strain MG infections.
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Table 4.1

Mean dose [colony forming units (CFU)] of ts-11 Mycoplasma gallisepticum
vaccine (ts-11MGV) for each 50 μL solution volume administered by in ovo
injection to layer embryos at 18 days (d) of incubation (doi)
Treatment1,2

Dose (CFU)

1 x 10-4

7.25 x 102

1 x 10-3

7.25 x 103

1 x 10-2

7.25 x 104

1 x 10-1

7.25 x 105

1

The ts-11MGV was plated from the original vaccine vial on 2 plates. The count was determined on a 10-4
dilution of the vaccine.
2
Treatments of live ts-11MGV were diluted in Marek’s disease diluent. The vaccine [1,000 CFU dose vial
(Vaxsafe® MG ts-11)] was resuspended in 50 mL of diluent and applied as 10-4, 10-3, 10-2, and 10-1
dilutions, respectively.
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Table 4.2

Mean percentage egg weight loss (PEWL) between 0-12, 12-18, and 0-18 days
of incubation (doi), hatchability of injected eggs containing viable embryos
(HI), and mean straight run hatchling body weight (BW) at 22 days (d) of
incubation (doi) in exposed diluent-injected control (EC) eggs and those
injected with 7.25 x 102, 7.25 x 103, 7.25 x 104, and 7.25 x 105 CFU of the ts11MG vaccine (ts-11MGV)

Treatment

EC1
7.25 x 102 CFU2
7.25 x 103 CFU3
7.25 x 104 CFU4
7.25 x 105 CFU5
Source of
variation
Pooled SEM
P-value

PEWL
PEWL
PEWL
HI7
0-12 d6
12-18 d
0-18 d
------------------------(%)----------------------

Hatchling BW8
(g)

7.09

3.94

11.08

97.24

39.81

7.09

3.59

10.67

97.48

39.70

7.15

4.00

11.12

96.15

40.00

7.13

4.15

11.29

96.43

39.94

7.06

4.01

11.08

97.93

40.16

0.090
0.856

0.196
0.080

0.207
0.063

1.463
0.727

0.299
0.595

1

At 18 doi, embryonated eggs injected with Marek’s diluent were incubated in the same hatcher with ts11MGV injected eggs.
2
102 CFU (colony forming unit) of ts-11MG was 10-4 dilution from resuspended vial of vaccine, per 50 μl
volume.
3
103 CFU of ts-11MGV was 10-3 dilution from resuspended vial of vaccine, per 50 μl volume.
4
104 CFU of ts-11MGV was 10-2 dilution from resuspended vial of vaccine, per 50 μl volume.
5
105 CFU of ts-11MGV was 10-1 dilution from resuspended vial of vaccine, per 50 μl volume.
6
Percentage of egg weight loss was calculated based on the difference from initial and final weight of 12
flat replicate started with 30 eggs/tray for each period (0-12), (12-18), and (0-18) doi.
7
Average percentage of injected at 18 d embryos that hatched successfully and were alive at pull time.
8
Hatchling BW was calculated from 12 basket replicates that had approximately 25 chicks each treatment.
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Table 4.3

Mean pre-pipped embryo, pipped embryo, and hatched chick mortality at 22
days (d) of incubation (doi) in exposed diluent-injected control (EC) eggs and
those injected with 7.25 x 102, 7.25 x 103, 7.25 x 104, and 7.25 x 105 CFU of the
ts-11MG vaccine (ts-11MGV)

Treatment
EC1
7.25 x 102 CFU
7.25 x 103 CFU
7.25 x 104 CFU
7.25 x 105 CFU
Source of variation
Pooled SEM
P-value

Pre-pipped embryo
Pipped embryo
Hatched chick
mortality2
mortality3
mortality4
-------------------------------------(%)----------------------------------0.00
0.00
2.92
0.33

0.00

2.06

0.29

0.36

3.18

0.00

0.33

2.86

0.00

0.00

0.94

0.204
0.577

0.215
0.568

0.988
0.501

1

At 18 doi, embryonated eggs injected with Marek’s diluent were incubated in the same hatcher with ts11MGV injected eggs.
2
Embryos externally pipped through the eggshell were alive but had not fully hatched at pull time at 22
doi.
3
Embryos that had externally pipped but were dead at pull time.
4
Full hatched chicks that were found dead in the hatch basket at pull time.
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Table 4.4

Mean body weight (BW) at 0 (BW0) and 21 (BW21) days (d) posthatch,
and BW gain between 0 and 21 d posthatch (BWG21) in exposed diluentinjected control (EC) eggs and those injected with 7.25 x 103, 7.25 x 104,
and 7.25 x 105 CFU of the ts-11MG vaccine (ts-11MGV)

Treatment

BW05
BW21
BWG21
------------------------(g)---------------------

EC1

39.60

183.67

144.00a

7.25 x 103 CFU2

39.50

185.67

146.00a

40.57

185.67

145.33a

40.63

176.67

136.67b

Pooled SEM

0.434

2.45

2.33

P-value

0.073

0.058

0.023

7.25 x 104 CFU3
7.25 x 105 CFU4
Source of Variation

a,b

Different letters denote significant difference within a column at P ≤ 0.05.
At 18 doi, embryonated eggs injected with Marek’s diluent were incubated in the same hatcher with ts11MGV injected eggs.
2
103 CFU of ts-11MGV was 10-3 dilution from resuspended vial of vaccine, per 50 μl volume.
3
104 CFU of ts-11MGV was 10-2 dilution from resuspended vial of vaccine, per 50 μl volume.
4
105 CFU of ts-11MGV was 10-1 dilution from resuspended vial of vaccine, per 50 μl volume.
5
BW0 is average chicks at hatch from approximately 330 chicks per treatment; average BW at 21 d;
BWG from 0 to 21 d of age.
All variables are calculated based on biological isolated units (3 units/treatment) and each unit had 25
birds.
1
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CHAPTER V
EFFECTS OF THE IN OVO ADMINISTRATION OF THE 6/85 MYCOPLASMA
GALLISEPTICUM VACCINE ON LAYER EMBRYO LIVABILITY,
POSTHATCH CHICK PERFORMANCE AND IMMUNITY,
AND SUBSEQUENT POSTHATCH RESPONSES TO
A VIRULENT M. GALLISEPTICUM CHALLENGE
5.1

Abstract
Mycoplasma gallisepticum (MG) is a pathogenic bacterium that impacts egg production

in layer chickens. Efficacy of the in ovo administration of a live 6/85-strain of MG vaccine
(6/85MGV) to layer embryos was evaluated. Amniotic injections were administered on 18 days
(d) of incubation (doi) and included a diluent-injected control and diluent containing 1.66 x 102
or 1.66 x 103 CFU of 6/85MGV. A total of 360 fertile layer hatching eggs in each treatment were
incubated in a single-stage incubator. At 22 doi, hatchability of injected live embryonated eggs
(HI) and hatch residue analyses were conducted. Due to space limitations, the 1.66 x 102 CFU
treatment group was terminated at 22 doi and was not included in the posthatch phase of the
study. The early posthatch immune response, including air sac and tracheal lesion scores, were
evaluated. Furthermore, birds in diluent-injected or 1.66 x 103 CFU 6/85MG-injected treatments
were subsequently challenged in the trachea with 50 μL of sterile saline or the virulent Rlowstrain of MG (RMG) at d 28 posthatch. The combined treatment groups in the posthatch phase
were: diluent-injected and sham-challenged (DS), diluent-injected and RMG-challenged (DR),
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6/85MG-vaccinated and sham-challenged (VS), and 6/85MG-vaccinated and RMG-challenged
(VR). Twenty chicks were allocated to each of 4 replicate biological isolation units (BIU) within
the each of the 4 treatment groups, and were raised through d 42 of posthatch age. One chick in
each treatment replicate was swabbed at hatch in the choanal cleft for 6/85MG detection. At d 28
of age, 10 birds per treatment replicate were swabbed for MG DNA detection and bled for MG
antibody production by serum plate agglutination (SPA) and ELISA tests. At 7 and 14 d postchallenge, all birds from each unit were swabbed for MG DNA detection by qPCR testing and
bled for quantitation of MG antibody production using SPA and ELISA analysis. Trachea and
bronchia were removed from 2 birds within each treatment replicate BIU for lesion scoring.
There were no significant treatment differences for HI, hatch residue, bird performance, or chick
mortality variables. At hatch, MG DNA was detected by qPCR in the 1.66 x 102 and 1.66 x 103
CFU treatments, and confirmed that the injected 6/85MGV was successfully transmitted to the
embryos. At d 28 of age, qPCR testing confirmed that 6/85MGV remained in the choanal cleft of
birds in the 1.66 x 103 CFU treatment group. Positive SPA test and ELISA titers were observed,
whereas these for controls remained negative. The in ovo administration of the 6/85MG vaccine
may be used to pragmatically provide layer pullets early protection against field-strain MG
infections. At 7 and 14 d post-challenge, there were significant vaccination × challenge
interactions for SPA results and for MG DNA in the choanal cleft. The levels of MG DNA were
higher in the DR treatment compared to the DS, VS, and VR treatments, and SPA results were
positive in the VS and VR treatments, but not in the DR and DS treatments. At 7 and 14 d postchallenge, 6/85MG vaccination resulted in significantly higher ELISA titers compared to the DS
and DR treatments. Across challenge treatment, vaccinated birds exhibited less tracheal and
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bronchial inflammation and less severe lesion hyperplasia than unvaccinated birds. It was
concluded that 1.66 x 103 CFU of the 6/85MGV delivered by in ovo injection can provide
improved protection against a virulent RMG challenge in layer pullets.
Key words: embryo, in ovo, layer, live 6/85 vaccine, Mycoplasma gallisepticum.
5.2

Introduction
Mycoplasma gallisepticum (MG) is a transmittable disease of poultry, affecting layer and

broiler chickens, and also turkeys and other avian species (Evans et al., 2005). Infection often
results in chronic respiratory disease that consists of rales, nasal discharge, and airsacculitis (Ley
and Yoder, 1997). While MG infection sometimes results in elevated flock mortality, it more
frequently results in lower feed conversion, lower carcass weights, increased carcass
condemnation, and increased medication expenses (Ley, 2003; Ley and Yoder, 1997). The
infection of meat-type flocks by MG is generally controlled with biosecurity strategies, including
all-in-all-out management. However, multi-age housing facilities, which include both layer and
breeding houses, cannot be controlled via all-in-all-out methods or depopulation (Kleven et al.,
1984). Mycoplasma gallisepticum also results in a loss of egg production in these facilities,
leading the poultry industry to adopt vaccination strategies to reduce the incidence of MG
infections (Carpenter et al., 1981; Levisohn and Kleven, 1981).
There are presently 3 live MG vaccines available for inoculating layer chickens, based on
3 different MG strains: the F strain of MG (FMG; F VAXMG, Intervet Schering Plough Animal
Health, Boxmeer, the Netherlands; Poulvac Myco F, Fort Dodge Animal Health, Fort Dodge,
IA), the 6/85 strain of MG (6/85MG; Mycovac- L, Intervet Schering Plough Animal Health,
Millsboro, DE), and the ts-11 strain of MG (ts-11MG; MG vaccine, Merial Select, Duluth, GA)
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(Evans et al., 2005; Kleven, 2008). Hens are routinely vaccinated prior to laying with the goal of
inoculating before contact with an MG infection (Levisohn and Kleven, 1981). Both live
attenuated strains or killed MG bacterin strains may be used to achieve effective inoculation
(Carpenter et al., 1981; Hildebrand et al., 1983; Whithear, 1996). The FMG vaccination is seen
as an effective method of protecting hens against most field strains for the duration of their life
(Kleven et al., 1990; Whithear, 1996; Hy-Line, 2013). Pullets are usually inoculated prior to the
start of lay [between 8 and 12 weeks (wk) of age] with a live attenuated vaccine or an oil
emulsion bacterin to reduce egg loss (Levisohn and Kleven, 1981; Whithear, 1996; Evans, et al.,
2005). Live attenuated vaccines can be administered by both a spray or eye drop, with bacterins
being delivered subcutaneously (Whithear, 1996). Both of these procedures are labor intensive.
Early research showed that FMG vaccination decreases egg production, however, the
decrease was notably less than one would find in birds infected with field strains of MG
(Carpenter et al., 1981). Evans et al. (2005) indicated that egg loss due to FMG vaccination may
be less apparent in the commercial industry. However, use of the FMG vaccine may be
implicated in reduced egg sizes, particularly from large to medium egg size (Branton et al.,
1999). Studies were previously conducted to evaluate effects of the in ovo injection of FMG at
18 days (d) of incubation (doi) on the hatchability of injected live embryonated eggs (HI)
(Elliott et al., 2017), posthatch bird survivability and immunity (Elliott et al., 2018), and possible
posthatch horizontal transmission of FMG (Elliott et al., 2019). Different doses (2.4 to 2.4 x 106
CFU) of the inoculum were evaluated. At 22 doi, FMG was detected in the trachea, mouth,
esophagus, yolk sac, and lumen of the duodenal loop (Elliott et al., 2017). In a subsequent study,
it was reported that in ovo injection of the lowest dose (2.4 CFU) had the least impact on
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livability and body weight (BW), but exhibited the lowest humoral immune response (Elliott et
al., 2018). In addition, it was observed that the posthatch BW of the birds belonging to the 2.4 x
102, 104, and 106 CFU FMG in ovo treatment groups was significantly lower compared to those
given the lower dosages and to those in a diluent-injected control group. When FMG was applied
in ovo at 18 doi, it was subsequently transmitted from vaccinated to unvaccinated birds when
they were in direct contact (Elliott et al., 2019).
The 6/85MG and ts-11MG vaccines do not result in posthatch BW decreases, however,
they are also limited in the level of protection they provide against field strain infections (Abdel-Motelib and Kleven, 1993; Evans et al., 2007; Kleven, 2008). The field isolate used to
produce the 6/85MG vaccine is known to have a low level of virulence as well as a low potential
for transmission from vaccinated to non-vaccinated chickens (Evans and Hafez, 1992; Ley et al.,
1997). Previous research (Chapter 3 of this dissertation) indicates that delivery of the 6/85MG
vaccine (6/85MGV) to layers may be potentially used to stimulate the immunity of birds against
subsequent field-strain MG challenges. Initial results (Chapter 3 of this dissertation) have
indicated that layer embryos can survive and hatch when in ovo-injected with a 6.25 x 104 CFU
of 6/85MG. However, HI was reduced by approximately 16 % when compared to those injected
with diluent alone or containing 6.25 x 102 CFU of 6/85MGV. This initial research also indicates
a need for further study, including the use of lower doses (i.e. 103 CFU) and the employment of a
larger sample size, to determine the appropriate dosage, and which ideally will have minimal
negative impacts on HI and posthatch growth and immunity.
Vaccinating layers posthatch with vaccine strains of MG has provides effective
protection against field-strain MG infections, which is associated with the displacement of field
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strains of MG in the trachea (Cummings and Kleven, 1986; Kleven et al., 1998; Hy-Line, 2014).
More virulent FMG vaccines tend to be more protective, when compared with other available
live MG vaccine strains (6/85MG and ts-11MG) (Abd-El-Motelib and Kleven, 1993; Kleven et
al., 1998). However, FMG has displayed negative impacts on HI and posthatch survivability
when administered to pullets at doses of 102 CFU or higher (Elliott et al., 2018). Therefore, the
goal of this experiment was to confirm that use of a live attenuated 6/85MG vaccine has potential
for eventual commercial use when delivered via in ovo injection. Its potential for providing
protection against field-strain MG infections was further explored by testing for posthatch
antibody production against MG and the response of vaccinated birds to a subsequent field-strain
[Rlow-strain of MG (RMG)] challenge.
5.3
5.3.1

Materials and Methods
Egg Incubation
A total of 1,080 fertile Hy-Line W-36 layer eggs, were obtained from a 45 wk-old MG-

clean commercial breeder flock (Hy-Line Company, Mansfield, GA). Eggs were incubated in
calibrated single stage NMC2000 NatureForm Incubators (NatureForm Incubator Company,
Jacksonville, Florida). Thirty eggs were randomly set in each of 12 replicate tray levels (blocks)
belonging to each of 3 treatment groups (diluent only-injected control, and 2 6/85MGV dosages
suspended in diluent). The treatment groups were randomly arranged on each tray level of the
incubator. At 12 doi, infertile eggs and those containing dead embryos were removed, and only
those eggs containing viable embryos were in ovo-injected in the amnion (AM) at 18 doi. The
treatment groups were re-randomized on each replicate tray level to avoid horizontal positional
effects in the incubator. The temperature and humidity settings in the incubator were 37.50 °C
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dry bulb and 29.44 °C wet bulb (55 % relative humidity), respectively, for the first 18 doi (setter
incubational phase). The relative humidity remained the same (28.75 °C wet bulb), but the
temperature was reduced to a 36.70 °C dry bulb temperature for the last 4 doi (hatcher
incubational phase). Three HOBO temperature/ humidity data loggers (Onset Computer
Corporation, Bourne, MA) were placed in the top, middle, and bottom tray levels of the
incubator to accurately record environmental conditions. Logger readings were recorded every
15 minutes (min) during both the setter and hatcher incubational phases.
5.3.2

In ovo treatment solution preparation and application
The 6/85MGV (NOBILIS® MG 6/85, MSD Animal Health, De Soto, KS) was

resuspended in Marek’s disease diluent [Poulvac Marek’s disease diluent (Zoetis, Parsippany,
NJ)] to achieve 2 concentrations in 10 x increments. The dilutions of the 6/85MGV were
prepared on the same d of injection. The 1 x 10-4 and 1 x 10-3 dilutions, respectively, contained
1.66 x 102 and 1.66 x 103 CFU of the organism in each 50 μL volume of solution that was
injected into the AM of each egg (Table 4.1). Manual AM injections of 6/85MGV were
performed following the procedures of Embrex, Inc. (2002). This same procedure was also
described in an earlier article by Elliott et al. (2017). All injections were performed by the same
individual to increase the consistency of injection methodology between eggs. Before injection,
the 6/85MGV was plated on Frey’s Mycoplasma agar (Frey et al., 1968) and incubated at 37 °C
to confirm vaccine viability and the actual dosage being delivered.
Localization of injections were verified by injecting dye into one embryonated egg from
each of the 3 treatment groups on each of the 12 replicate tray levels. The eggs were injected
with Coomassie brilliant blue R-250 dye (Genlantis, San Diego, CA) and opened to locate the
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site of injection including the AM, body proper, and yolk sac, and the stage of embryonic
development using the Embrex embryo stage scoring procedure developed by Zoetis (Avakian,
2006) and further employed by Sokale et al. (2017). After injection of the live embryonated eggs
from each treatment replicate group, they were randomly allocated to 6 sections within each of 2
hatching baskets on each of 3 tray levels (one treatment per level) for the hatching phase that
coincided with the treatment replicate groups represented in the setter phase. Hatching baskets
containing eggs that received the high (1.66 x 103 CFU) 6/85MGV dosage were placed at the
bottom of the hatcher, and the diluent only-injected control and 1.66 x 102 CFU treatment groups
were placed in that consecutive order beginning at the top portion of the hatcher to eliminate
cross-contamination via chick droppings. The incubator and data loggers were monitored daily to
ensure their proper function and that the eggs were incubated under optimum conditions.
5.3.3

Prehatch Egg Weight Loss and Hatch Variables
Egg residues were marked, counted, and subsequently opened for embryonic

development stage confirmation (Mauldin and Wilson, 2014). Percentage egg weight loss
(PEWL) in the 0-12, 12-18, and 0-18 doi intervals; late embryonic (dead prior to internal pip),
pre-pipped embryo (dead prior to external pip), pipped embryo (dead after external pip but not
fully emerged from the shell), and hatched chick (dead shortly after hatch) mortalities (Elliott et
al., 2017); HI; and hatchling BW were determined at 22 doi. Bird husbandry, handling,
sampling, and euthanasia procedures were approved by a USDA-ARS Animal Care and Use
Committee (Mississippi State, MS). In each of the 3 treatment groups on each of the replicate
tray levels, mean straight run hatchling BW was determined, and one chick was randomly
selected for additional analysis. Each chick (36 total chicks) was weighed, euthanized, and their
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choanal clefts were immediately swabbed for MG DNA analysis. Birds in the diluent onlyinjected control, and 1.66 x 102 and 1.66 x 103 CFU dosage treatment groups were swabbed in
that order.
5.3.4

Posthatch Pen Assignments of in ovo Treatment Groups and Posthatch Variables
Through D 28
Hatched chicks were counted and weighed and mean hatchling BW was determined for

each treatment replicate group. Only females were used in the posthatch phase of the study.
Female chicks from each replicate tray level that belonged to either the diluent-injected control
or 1.66 x 103 CFU treatment were pooled (approximately 160 birds in each treatment). Due to
space limitations, the 1.66 x 102 CFU treatment group was terminated at 22 doi and was not
included in the posthatch phase of the study. The birds belonging to that treatment group were
weighed before being humanely euthanized. It was reasoned that this lowest dosage treatment
group could be practically eliminated, as its hatch results were not statistically different from the
other treatments. Twenty chicks from each of the 2 treatment groups were randomly assigned to
each of 8 replicate biological isolation units (BIU) that occupied a common room, and were
raised through d 28 of posthatch age. The 8 replicate BIU belonging to each of the 2 treatment
groups were arranged in the room, so that separate ventilation systems serviced the 8 replicate
BIU that belonged to a common treatment. Each BIU measured 1.42 m x 0.65 m (0.92 m2).
Stocking density was 0.04 m2 per bird to meet Hy-Line W-36 breeder pullet recommendations
(Hy-Line Red Book, Hy-Line International, 2014).
Each BIU had a bell drinker and a circular gravity-fed feeder that would accommodate up
to 12 birds simultaneously. A flat feed tray was provided for the first wk posthatch before the
feeder was used. All birds had ad libitum access to water and feed during the entire grow-out
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period. The pullets were fed a crumble starter diet that met NRC requirements (NRC, 1994) for
the first 2 wk posthatch, and was replaced with a crumble diet through d 42 of age. According to
Hy-Line recommendations for W-36 pullets, the lighting program provided 21 hours (h) of light
and 3 h of dark in the room during the first wk, and the period of light was reduced by 1 h every
wk so as to reach 8 h of dark by d 42 of age. Furthermore, as recommended, room air
temperature was 34◦C on the first d posthatch and was lowered by 2 to 3◦C daily until 21◦C was
reached. Birds belonging to the diluent-injected control treatment were monitored daily before
those belonging to the 6/85MGV treatments, in order to prevent possible cross-contamination.
Birds in the 1.66 x 103 CFU treatment group were likewise monitored daily, in that respective
order, to further prevent possible cross-contamination.
After chick placement in each replicate BIU, mean female chick BW was determined on
d 0 (BW0) and 28 (BW28) posthatch. The difference between mean BW0 and BW28 was used
to calculate mean 0 to 28 d BW gain (BWG28) for each replicate BIU. Chick mortality was
monitored daily, with dead chicks being weighed on a daily basis. Furthermore, at d 28 of age,
all birds were weighed, and 50 % of the birds in each BIU were swabbed and bled.
5.3.5

RMG Challenge Treatment
Birds in 4 of the 8 replicate pens in each in ovo treatment group were either sham-

challenged or RMG-challenged at d 28 posthatch. A 24 h broth culture of RMG with a titer of 1
x 106 color-changing CFU was used for the challenge treatment. Sham and RMG challenges
were applied via tracheal gavage. The diluent-injected control and the 1.66 x 103 CFU treatment
groups were then divided into 4 treatment groups. Four replicate BIU belonging to each of the 4
treatment groups occupied the same row in the room. The following 4 treatment groups were
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designated as follows: controls in ovo-injected with diluent and sham-challenged with 0.1 mL of
sterile Frey’s media (Frey et al., 1968) (DS); controls in ovo-injected with diluent and challenged
with 0.1 mL of RMG (DR); 6/85MGV-vaccinated and sham-challenged with 0.1 mL of sterile
Frey’s media (VS); and 6/85MGV-vaccinated and challenged with 0.1 mL of RMG (VR).
5.3.6

Posthatch variables after d 28
Mean female chick BW was determined on d 35 (BW35), and 42 (BW42) ; the difference

between BW28 and BW35 was used to calculate mean 28 to 35 d BW gain (BWG35); and the
difference between BW35 and BW42 was used to calculate mean 35 to 42 d BW gain (BWG42)
for each replicate BIU. A subsample of birds (5 from each BIU) were weighed, swabbed, and
bled at 7 and 14 d post-challenge. At 7 and 14 d post-challenge, birds were necropsied and air
sac and tracheal tissues samples were visually examined for possible lesions, and the tracheas of
2 birds from each BIU (8 birds/treatment) were removed and microscopically examined for
histological lesions. Likewise, the bursas of these same birds were removed and weighed, and
the bursa to bird BW ratio was calculated at d 35 (BR35) and d 42 (BR42) posthatch. Birds that
were not swabbed and bled were either sham-challenged or RMG-challenged. Those birds were
not swabbed and bled on d 28 (pre-challenge) to avoid extra stress that might be added to the
stress of challenge that they subsequently received.
5.3.7

Choanal Cleft Swabbing
At hatch and at d 28, 35, and 42 posthatch, pre-wetted sterile swabs in phosphate-

buffered saline were used to swab the choanal cleft of the birds for 6/85MG DNA detection. All
swabs were suspended in 100 μL of phosphate-buffered saline and extracted using a BioSprint
96 One-For-All Kit (Qiagen, Valencia, CA). All swab samples were run in duplicate using a
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7500 Fast Real Time PCR System (Applied Biosystems, Foster City, CA). A specific MG primer
and probe were used for DNA analysis. A 25 μL sample volume was used for PCR testing,
which included 2.5 μL of forward primer, 2.5 μL of probe, 12.5 μL of Taqman Universal Master
Mix (Applied Biosystems, Foster City, CA), and 2.5 μL of extracted DNA in sterile water (Raviv
et al., 2008). A 22.5 μL volume of master mix was loaded into each well of a 96-well-plate, and
2.5 μL of sample DNA was then subsequently added to each well. Each plate included a negative
control that contained sterile water only, and a positive control contained RMG to design a
standard curve including 10-1, 10-2, and 10-3 dilutions. The protocol by Nascimento et al. (1991)
was used for 6/85MG detection by PCR. The qPCR cycling process used was as described by
Raviv et al. (2008).
5.3.8

Blood sampling and immunology
After 50 % of the birds were swabbed at d 28 of age, they were immediately bled and

approximately 3 mL of blood from each bird was collected and kept at room temperature for 2 h.
After clotting, sera were centrifuged and poured into labelled vials and stored at 4°C until use.
For detection of IgM antibodies against MG, SPA analysis was conducted, and only SPApositive samples were further analyzed by ELISA for the presence of IgG antibodies against
MG. One drop of MG antigen was added to each individual 30 μL volume of serum. The
mixtures were shaken on a Clinical Rotator (Fisher Scientific, Hampton, NH) for 3 to 5 min.
5.3.9

Histopathology and scoring methods
A section of distal trachea from each bird was collected and immediately placed in 10%

neutral buffered formalin. Distal tracheal sections for microscopic analysis were sampled from 3
locations (proximal, middle, and at the level of the tracheal bifurcation). Tissues were processed
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by conventional methods, embedded in paraffin, sectioned at 5 microns, and stained with
hematoxylin and eosin (H & E). Tracheal cross sections were then examined microscopically.
The histopathologist was blinded to the source of the treatment group. The pathology grading
system consisted of a numerical score ranging from 0 to 5. The 3 sections from each distal
tracheal section were evaluated for the presence, type, and severity of inflammation and the
presence or absence of serosal lymphoid nodular aggregates. Mucosal and submucosal changes
were evaluated according to the following scoring system: 0 (no significant microscopic
changes); 1 (mild mucosal and/or submucosal inflammation); 2 (moderate mucosal and/or
submucosal inflammation); 3 (marked/severe mucosal and/or submucosal; 4 (mucosal epithelial
hyperplasia); and 5 (serosal lymphoid nodules).
5.4

Statistical Analysis
A randomized complete block design was employed for the hatch results, which included

HI, egg residue analyses, and hatchling BW, where incubator tray level was considered as the
blocking factor. All treatments were randomly assigned to each block (tray level). Posthatch
BW0, BW28, BW35, and BW42; MG DNA detection by qPCR; and MG antibodies detected by
SPA and ELISA tests were analyzed using a completely randomized experimental design, where
replicate BIU was the experimental unit. Hatch and posthatch variables data were analyzed by
Two-way ANOVA of SAS 9.4 (SAS Institute, 2014) employing PROC MIXED. Means
separations were performed using Fisher’s protected least significant difference in the event of
significant global effects. Median tracheal and bronchial inflammation and LM nodule
histopathology scores were analyzed separately using the Wilcoxon rank-sum non-parametric
test. Statements of significance were based on P ≤ 0.05 unless otherwise stated.
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5.5
5.5.1

Results
Prehatch, Hatch, and Pre-Challenge Posthatch Variables
The prehatch and hatch variables in the diluent only-injected control and 2 6/85MGV

treatment groups (1.66 x 102 and 1.66 x 103 CFU) were statistically compared. Mean 0-12 d
PEWL, 12-18 d PEWL, 0-18 d PEWL, HI, and hatchling BW were not significantly different
between these 3 treatment groups (Table 5.2). In addition, there were no significant differences
between the 3 treatment groups for late embryo, pre-pipped embryo, pipped embryo, and hatched
chick mortalities (Table 5.3). Furthermore, there were no significant differences between the
diluent only-injected control and 1.66 x 103 6/85MGV treatment groups for BW0, BW28, or
BWG28 between d 0 and 28 posthatch (Table 5.4).
The MG DNA results from the choanal cleft swabs taken at hatch and at d 28 posthatch,
and the IgM and IgG serologic responses at d 28 posthatch, are shown in Table 5.5. No MG
DNA was detected in the choanal cleft of birds in the diluent-injected control treatment at hatch
or on d 28 posthatch, and using SPA analysis, the serum samples taken at these times from the
diluent only-injected control treatment group tested negative for IgM against MG. However,
there was a significant (P < 0.0001) effect due to 6/85MGV for the presence of MG DNA in the
choanal cleft of birds at hatch and at d 28 posthatch. In addition, significant (P < 0.0001) IgM
and IgG serologic responses to 6/85MGV were likewise observed at d 28 posthatch. The
percentage of birds that tested positive for the presence of MG DNA at hatch was higher in the
1.66 x 102 and 1.66 x 103 CFU treatment groups in comparison to the diluent-injected treatment
group. Also, the percentage of birds that tested positive for the presence of MG DNA at d 28
posthatch was higher in the 1.66 x 103 CFU treatment compared to the diluent treatment (Table
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5.5). At d 28 posthatch, the percentage of birds exhibiting IgM and IgG responses in the 1.66 x
103 CFU treatment group was higher in comparison to the diluent only-injected control treatment
group.
5.5.2

Posthatch performance, DNA detection, and immune response variables
There were no significant main or interaction effects due to 6/85MGV and RMG-

challenge on BW28, BW35, BW42, BWG35, BWG42, BR35, or BR42 at d 7 and 14 postchallenge during the grow out period (Table 5.6). There were also no observed posthatch bird
mortalities in any of the treatment groups. The MG DNA results of the choanal cleft swabs and
IgM and IgG serological responses taken at d 35 and 42, are shown in Table 5.7. There were
significant (P ≤ 0.0001) 6/85MGV in ovo × RMG challenge interactions for the percentage of
birds that tested positive for the presence of MG DNA at d 35 and 42. Furthermore, there was a
significant (P = 0.035) 6/85MGV in ovo × RMG challenge interaction for a serologic IgM
response to MG at d 35 posthatch. The percentage of birds that tested positive for the presence of
MG DNA at d 35 was not different in the DS treatment group in comparison to the VS treatment
group. However, the percentage of birds that tested positive for the presence of MG DNA at d 35
and 42 was higher in the DR treatment group in comparison to the DS and VS treatment groups,
and MG DNA detection was higher in the VR compared to the DR treatment group. At d 35
posthatch, the IgM percentages for birds in the VS and VR treatment groups were higher in
comparison to the DR treatment group. Furthermore, IgM percentages for birds in the DR
treatment group were higher than that in the DS treatment group. There was a significant (P <
0.0001) main effect due to in ovo 6/85MGV treatment on the serologic IgG response at d 35 and
42 posthatch. The IgG percentages for birds at d 35 and 42 posthatch were higher in the 1.66 x
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103 CFU treatment in comparison to the diluent-injected control treatment. Furthermore, there
was a significant (P = 0.001) main effect due to RMG-challenge for a serologic IgG response to
6/85MGV at d 42 posthatch. The IgG percentages for birds at d 42 posthatch were higher in the
RMG-challenge treatment in comparison to those in the sham-challenge treatment. There were
no significant in ovo × challenge treatment interactions for IgM at d 42 or for IgG percentages on
d 35 and d 42.
5.5.3

Histopathology and scoring
At 7 d post-challenge, mean trachea and bronchi inflammation scores were significantly

(P = 0.046 and P = 0.019, respectively) higher in the DR treatment birds in comparison to those
in the DS, VS, and VR treatment groups (Table 5.8). Moderate mucosal inflammation in the
trachea and bronchi was observed in the DR treatment group, whereas the other groups showed
no significant microscopic changes. There were no significant microscopic differences among all
treatment groups for trachea and bronchi LM nodules at 7 d post-challenge (Table 5.8).
However, at 14 d post-challenge, tracheal and bronchial inflammation scores were significantly
(P = 0.001 and P = 0.005, respectively) higher in the DR treatment birds in comparison to those
in the DS, VS, and VR treatment groups. Moderate tracheal and bronchial mucosal inflammation
was observed in the DR treatment compared to the other treatment groups. In addition, LM
nodule scores in the trachea and bronchia were likewise significantly (P < 0.0001 and P = 0.006,
respectively) higher in the DR treatment in comparison to the DS, VS, and VR treatments (Table
5.9). Overall, birds in the DR treatment group had higher incidences of tracheal and bronchial
lesions in comparison to the DS, VS, and VR treatment groups.
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5.6

Discussion
A 1.66 x 103 CFU 6/85MGV was not tested in Chapter 3 of this dissertation. However,

the 1.66 x 103 CFU 6/85MGV treatment elicited a greater serologic response than did a 1.66 x
102 CFU dosage of 6/85MGV in this current study. Furthermore, a 1.73 x 104 CFU 6/85MGV
treatment in the previous study (Chapter 3) led to a decrease in HI and an increase in posthatch
bird mortality. Without negatively impacting chick hatchability and posthatch survivability, a
1.66 x 103 CFU dosage of 6/85MGV can be safer than a 1.73 x 104 CFU dosage, while eliciting a
better serological response than a 1.66 x 102 CFU dosage of 6/85MGV.
Ley et al. (1997) reported that subsequent clinical signs such as morbidity or mortality
that would be suggestive of a pathogenic MG infection were not observed in layer pullets sprayvaccinated with 6/85MG. Likewise, the combined pre-hatch and hatch results suggest that
injection of 6/85MGV in the AM at 18 doi had no negative impact on the late embryo
development and subsequent hatch variables in the current study. The pre-hatch and hatch results
of the 1.66 x 102 CFU in ovo treatment group in this study were also similar with those of the
previous report in Chapter 3, in which the effects of a 1.73 x 102 CFU dosage of the 6/85MGV
were tested. Although the HI and hatch residue analysis results in response to the 2 6/85MGV
dosages tested were not significantly different from those in the diluent only-injected control
treatment, in the study by Elliott et al. (2017), the HI of eggs injected in ovo with 2.4 x 102 CFU
of FMG was reduced to 87.50 %, which was significantly lower in comparison to that in diluentinjected controls, and which exhibited an HI of 97.7 % . Furthermore, Elliott et al. (2017)
reported that the pipped embryo and hatched chick mortality rates in the 2.4 x 102 CFU dosage
treatment group were 4.30 % and 4.10 %, respectively. Elliott et al. (2017) did not evaluate a 2.4
x 103 CFU dosage of FMG. However, a 2.4 x 102 CFU dosage or higher of FMG was found to
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have a negative impact on HI and posthatch chick mortality. This contrasts with the 1.66 x 103
CFU dosage of 6/85MGV used in the current study, which was observed to have no negative
effects on HI or posthatch chick mortality. These contrasting results could be attributed to the
greater virulence of FMG compared to that of 6/85MGV. Although FMG has been found to
successfully displace field strains of MG such as K2501 and K2582 (Kleven et al., 1990) and
RMG (Kleven et al., 1998) in layer flocks, its negative effects on HI and posthatch chick
mortality when administered by in ovo injection at dosages comparable with in ovo-injected
6/85MGV reduce its potential for in ovo application.
Bird BW, BWG, and mortality between 0 and 28 d posthatch were not affected by an in
ovo 6/85MGV prior to challenge (d 28), or between 28 and 42 d posthatch due to an RMG
challenge (d 28). This was in agreement with Viscione et al. (2008), who showed no adverse
impact on layer BW, BWG, and mortality between 20 and 47 wk of posthatch age when pullets
were gavage-inoculated at 10 wk of posthatch age with 106 CFU of 6/85MG and that received an
overlay inoculation of FMG at 22 or 45 wk. Levisohn et al. (1983) did not report the results of
the effects of FMG or virulent RMG infections introduced at 14 d of age on broiler chick
mortality. Nevertheless, they did observe similar results to that of Viscione et al. (2008) for
broiler BW between 0 and 12 d after a tracheal FMG inoculation. Minimal numerical (nonsignificant) decreases in BW occurred after the birds were introduced to 3.2 x 108 CFU of the
FMG organism. However, significant marked depressions in broiler BW were observed at 8 and
12 d after a tracheal inoculation of 3.0 x 108 CFU of the RMG organism (Levisohn et al., 1983).
The results of Levisohn et al. (1983) and Viscione et al. (2008) are similar concerning the effects
of a pre-lay inoculation of FMG on subsequent BW, and show that despite differences in bird
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type and the doses and timing of FMG inoculation, it has minimal effects on BW in the early
phases of growth as well as after sexual maturity. Likewise, in the current study, the in ovo
injection of 1.66 x 103 CFU of 6/85MGV did not affect subsequent chick BW and BWG. It also
did not lead to an increase in posthatch chick mortality. The results of this study and that of
Viscione et al. (2008) indicate that whether or not 6/85MGV is administered by in ovo injection
or later in the prelay pullet period, that bird growth is not adversely affected.
In a subsequent study by Elliott et al. (2018), it was reported that the in ovo injection of
2.4 x 102 CFU of FMG caused commercial layer chicks to experience over a 50 % mortality
within the first 2 wk posthatch. In addition, Elliott et al. (2018) observed that the posthatch BW
of birds at 6 wk posthatch belonging to the 1 x 106 CFU FMG in ovo treatment group was
significantly lower compared to those given lower dosages (1 x 104, 1 x 102, and 1 x CFU).
Furthermore, those given 1 x 104 CFU of FMG had a lower BW than those given 1 x CFU of
FMG, and those given 1 x CFU of FMG had a lower BW than diluent-injected and non-injected
controls. Conversely, in the current study, the in ovo injection of 1.66 x 102 CFU of 6/85MGV
did not affect chick BW and did not lead to an increase in posthatch chick mortality.
Administration of the 6/85MGV by in ovo injection at 18 doi provided a level of
protection for layer pullets against an RMG challenge at d 28 posthatch. The presence of MG
DNA in birds in the VR treatment was higher in comparison to those in the other treatment
groups. The VR treatment elicited a greater serologic response than did the diluent treatment at d
7 and 14 post-challenge. The tracheal and bronchial inflammation scores of birds in the VR
treatment group were also lower in comparison to those in the DR treatment group. In ovoinjected 6/85MGV provided an early protection for pullets, which was evidenced by 8- and 5125

fold higher IgG levels in those birds belonging to the VR treatment group at d 7 and 14 postchallenge, respectively, in comparison to those in the DR treatment group. This suggests that
when 6/85MGV is applied at 18 doi, subsequent high serum IgG levels may effectively clear the
birds of an RMG infection and provide the birds with adequate protection by d 7 and 14 postchallenge. The dramatic increase in serum IgG titers observed in the VR group could have
triggered the memory B cells due to the early in ovo-vaccination of 6/85MGV. This is an
important indication of the initiation of long-term protection and high memory responses against
a field-strain infection (Razin et al., 1998). Evans et al. (2007) intratracheal-vaccinated pullets at
10 wk of posthatch age with 108 CFU of MYCOVAC-L and followed that with RMG challenges
at 22 or 45 wk of age. The MYCOVAC-L vaccinated pullets that were not challenged with RMG
did not show stronger serological responses in comparison with challenged groups, which agreed
with the results of the current study. It is well known that 6/85MGV colonizes the upper
respiratory tract, but results concerning the presence of MG DNA in various tissues of 6/85MGvaccinated birds are not consistent and differences in bird age cause further inconsistencies
(Kleven et al., 1998; Ley et al., 1997). The virulence level of 6/85MG and its route of
vaccination could play major roles for its efficacy and the consistency of the physiological
response of birds. Kleven et al. (1998) found that the serological responses to 6/85MG tend to be
negative. Furthermore, Kleven et al. (1998) observed that a 6/85MG vaccine administered to
pullets by coarse spray and eye drop at 6 wk of age was not able to displace RMG administered
by eye drop at 8 wk of age. However, the results of this study showed that in ovo-vaccinated
pullets had continuous serological responses. Without negatively impacting chick hatchability,
posthatch survivability, and tracheal and bronchial lesions, a 1.66 x 103 CFU dosage of
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6/85MGV administered by in ovo injection in the AM at 18 doi can be safer while eliciting a
better serological response and while providing early protection against a field-strain MG
infection such as RMG.
In conclusion, effects of the in ovo-injection of 6/85MGV in the AM on HI, hatch
residue, posthatch performance, and serum serology were determined. In addition, pullets
received an RMG challenge at d 28 of posthatch age. This was performed to determine whether
or not in ovo 6/85MGV provides early protection against a field strain MG infection concomitant
with higher antibody production and minimal adverse effects. The findings in this study revealed
that a 1.66 x 103 CFU dosage of 6/85MGV resulted in greater embryo hatchability and posthatch
pullet performance when injected in the AM at 18 doi. Furthermore, a 1.66 x 103 CFU injection
of 6/85MGV in the AM was found to be more effective compared to a 1.73 x 104 CFU dosage
that was administered in Chapter 3. This was confirmed by the MG DNA, IgM, and IgG results
when 6/85MGV was injected at 18 doi. When injected in the AM, the 1.66 x 103 CFU treatment
group exhibited a humoral response at d 28 posthatch with no negative impact on chick
mortality. However, in the previous study of Chapter 3, the 1.73 x 104 CFU treatment injected in
the AM resulted in a higher hatched chick mortality when compared to the other treatment
groups. Trachea and bronchi lesion scores of pullets were significantly affected when they were
inoculated at d 28 of age with RMG, but showed that birds that were in ovo-vaccinated with
6/85MGV exhibited no significant microscopic lesions. These results indicate that the 1.66 x 103
CFU treatment injected in the AM provides protection against MG virulent strain infections and
would be the best candidate for pragmatic commercial application. This is further supported by
the fact that it did not lead to embryo and posthatch chick mortalities, but at the same time
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elicited a humoral response. In the future, it would be more definitive if such examined effects
would include an RMG challenge along with infectious bronchitis virus and/or E. coli challenges
to determine the efficacy of 6/85MGV in conferring full protection against RMG when provided
in combination with these other infectious challenges.
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Table 5.1 Mean dose [colony forming units (CFU)] of 6/85 Mycoplasma gallisepticum
vaccine (6/85MGV) for each 50 μL solution volume administered by in ovo
injection to layer embryos at 18 days (d) of incubation (doi)
Treatment1,2

Dose

1 x 10-4

1.66 x 102

1 x 10-3

1.66 x 103

1

6/85 Mycoplasma gallisepticum was plated from the original vaccine vial on 2 plates. The count was
determined on a 10-4 dilution of the vaccine.
2
Treatments of live 6/85MGV were diluted in Marek’s disease diluent. The vaccine [1000 CFU dose
vial (NOBILIS® MG 6/85)] was resuspended in 50 mL of diluent and applied as 10-4 and 10-5
dilutions, respectively.
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Table 5.2
Mean percentage egg weight loss (PEWL) between 0-12, 12-18, and 0-18 days
of incubation (doi), hatchability of injected eggs containing viable embryos (HI), and mean
straight run hatchling body weight (BW) at 22 days (d) of incubation (doi) in diluent-injected
control eggs and those injected with 1.66 x 102 and 1.66 x 103 CFU of the 6/85MG vaccine
Treatment

PEWL
PEWL
PEWL
HI5
4
0-12 d
12-18 d
0-18 d
---------------------------(%)--------------------------

Hatchling
BW6
(g)

Diluent1

7.27

3.97

11.24

96.18

40.14

1.66 x 102 CFU2

7.36

4.02

11.38

97.07

40.38

1.66 x 103 CFU3

7.28

4.00

11.27

96.41

40.47

Pooled SEM

0.080

0.047

0.117

1.180

0.323

P-value

0.516

0.557

0.492

0.739

0.583

Source of variation

1

At 18 doi, embryonated eggs injected with Marek’s diluent were incubated in the same hatcher with
6/85MGV-injected eggs.
2
1.66 x 102 CFU of 6/85MG in a 50 μl injection volume was produced by a 10-4 dilution of a resuspended
vial of vaccine.
3
1.66 x 103 CFU of 6/85MG in a 50 μl injection volume was produced by a 10-3 dilution of a resuspended
vial of vaccine.
4
Percentage egg weight loss was calculated based on the difference between initial and final weight for
each period (0-12), (12-18), and (0-18) doi, and dividing that by initial egg weight in each time period.
5
Average percentage of injected 18 d embryos that hatched successfully and were alive at the time when
hatch was pulled.
6
Hatchling BW (straight run) was calculated from 12 basket replicates that had approximately 25 chicks
each replicate each treatment.
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Table 5.3

Mean pre-pipped embryo, pipped embryo, late embryonic mortality, and
hatched chick mortality at 22 days (d) of incubation (doi) in diluent-injected
control eggs and those injected with 1.66 x 102 and 1.66 x 103 CFU of the
6/85MG vaccine

Treatment

Pre-Pipped
Pipped
Hatched
embryo
embryo
chick
5
6
mortality
mortality
mortality7
--------------------------------------(%)------------------------------------

Late embryonic
mortality4

Diluent1

2.47

1.27

0.00

0.32

1.66 x 102 CFU2

1.67

0.96

0.00

0.00

1.66 x 103 CFU3

2.26

0.70

0.70

0.35

1.167
0.779

0.821
0.785

0.388
0.135

0.393
0.621

Source of variation
Pooled SEM
P-value
1

At 18 doi, embryonated eggs injected with Marek’s diluent were incubated in the same hatcher with
6/85MGV injected eggs.
2
1.66 x 102 CFU of 6/85MG in a 50 μl injection volume was produced by a 10-4 dilution of a resuspended
vial of vaccine.
3
1.66 x 103 CFU of 6/85MG in a 50 μl injection volume was produced by a 10-3 dilution of a resuspended
vial of vaccine.
4
Embryos that died and had not pipped the eggshell at time of hatch.
5
Embryos that pipped externally but were found dead at time of hatch.
6
Embryos that pipped externally through the eggshell and were alive, but had not fully completed the
hatching process at time of pull at 22 doi.
7
Fully hatched chicks that were found dead in the hatch basket at time of hatch.
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Table 5.4 Mean body weight (BW) at 0 (BW0) and 28 (BW28) days (d) posthatch, and BW
gain between 0 and 28 d posthatch (BWG28) in diluent-injected control eggs and
those injected with 1.66 x 102 and 1.66 x 103 CFU of the 6/85MG vaccine
Treatment

BW02

BW28

BWG28

-------------------------(g)----------------------Diluent

39.91

283.08

243.17

1.66 x 103 CFU1

39.93

275.26

235.33

Pooled SEM

0.250

3.340

3.274

P-value

0.962

0.142

0.135

Source of variation

1

103 colony forming units (CFU) of 6/85MGV in a 50 μl injection volume was produced by a 10-3
dilution of a resuspended vial of vaccine.
2
BW0 is average chicks at hatch; BW28 is average chicks at 28 d of age (d); BWG28 is average BW
gain from 0 to 28 d. All variables are calculated based on 20 birds placed in each pf 8 isolation units
within each treatment.
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Table 5.5
Mean percentage of birds in the diluent-injected control (diluent), and 1.66 x
2
10 and 1.66 x 103 CFU 6/85MGV treatment groups that tested positive for MG DNA in the
choanal cleft at 22 days (d) of incubation (doi) (Hatch DNA) and at d 28 posthatch (D 28
DNA); and serum IgM (D 28 IgM) and IgG (D 28 IgG) serologic responses at 28 d posthatch
Treatment

Hatch DNA4
D 28 DNA5
D 28 IgM6
---------------------(%)---------------------

D 28 IgG7
(mg/dL)

Diluent1

0.00b

0.00b

0.00b

54.13b

1.66 x 102 CFU2

91.67a

-

-

-

1.66 x 103 CFU3

100.00a

40.00a

100.00a

694.67a

Pooled SEM

6.810

7.396

-

80.649

P-value

< 0.0001

< 0.0001

< 0.0001

< 0.0001

Source of variation

a,b

Different letters denote significant difference within a column at P ≤ 0.05.
Diluent is a control treatment embryos that injected with 50 μl of Marek’s diluent in the amnion (AM)
only at 18 doi by manual injection with a 50 μl volume.
2
1.66 x 102 CFU of 6/85MG in a 50 μl injection volume was produced by a 10-4 dilution of a resuspended
vial of vaccine.
3
1.66 x 103 CFU of 6/85MG in a 50 μl injection volume was produced by a 10-3 dilution of a resuspended
vial of vaccine.
4
Birds were swabbed at pull time in the choanal cleft for MG DNA detection via PCR: n=12 chicks per
treatment.
5
Only diluent and 1.66 x 103 CFU treatment chicks were raised and those in the 1.66 x 102 CFU treatment
were humanely euthanized at pull time due to space limitations and hatch success. Diluent and 103 CFU
birds were swabbed at d 28 of age in the choanal cleft for MG DNA detection via PCR: n= 80 chicks per
treatment.
6
Birds were bled at d 28 of age for serum plate agglutination (SPA) to test for IgM antibodies against
MG: n=80 chicks per treatment.
7
Birds were bled at d 28 of age for ELISA to test for IgG antibodies against MG: n=80 chicks per
treatment.
1
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Table 5.6
Mean BW at 28 (BW28), 35 (BW35), and 42 (BW42) days (d) posthatch; BW
gain between 28 and 35 (BWG35), 28 and 42 (BWG42) d posthatch; and bursa to bird BW
ratio at d 35 (BR35) and 42 (BR42) posthatch
Treatment1
In ovo
Diluent
1.66 x 103 CFU
SEM
Challenge
Sham
Challenge
SEM
In ovo×Challenge
DS2
DR3
VS4
VR5
SEM
P-value
In ovo
Challenge
In ovo×Challenge

BW286

BW35

BW42

BWG35

BWG42

BR35

BR42

---------------------------------------(g)-------------------------------------276.80 388.88
983.73
100.43
706.93
0.58
0.26
279.18 376.15
985.98
95.68
706.80
0.57
0.26
8.614
8.664
13.457
2.751
8.707
0.021 0.012
275.53
280.45
8.614

383.13
381.90
8.664

987.28
982.42
13.4571

99.35
96.75
2.751

711.75
701.98
8.707

0.58
0.56
0.021

0.25
0.27
0.012

272.45
281.15
278.60
279.75
12.182

394.25
383.50
372.00
380.30
12.253

987.25
980.20
987.30
984.65
19.031

101.10
99.75
97.60
93.75
3.890

714.80
699.05
708.70
704.90
12.313

0.60
0.55
0.56
0.57
0.030

0.245
0.266
0.255
0.267
0.017

0.784
0.569
0.663

0.146
0.888
0.275

0.868
0.720
0.871

0.088
0.348
0.651

0.989
0.265
0.495

0.646
0.329
0.209

0.631
0.177
0.6915

1

Treatments included birds that were either diluent or 1.66 x 103 CFU 6/85MGV in ovo-injected and that
were either sham-challenged or RMG-challenged at d 28 of age.
2
Diluent-injected and sham-challenged (DS) treatments were manually injected with 50 μl of Marek’s
diluent in the amnion (AM) at 18 d of incubation (doi) and were tracheal-gavaged with 0.1 mL of diluent
at d 28 posthatch.
3
Diluent-injected and RMG-challenged (DR) treatments were manually injected with 50 μl of Marek’s
diluent in the AM at 18 doi and were tracheal-gavaged with 0.1 mL of RMG at d 28 posthatch.
4
6/85MG-vaccinated and sham-challenged (VS) treatments were manually injected with 50 μl of Marek’s
diluent in the AM at 18 doi and were tracheal-gavaged with 0.1 mL of diluent at d 28 posthatch.
5
6/85MG-vaccinated and RMG-challenged (VR) treatments were manually injected with 50 μl of Marek’s
diluent in the AM at 18 doi and were tracheal-gavaged with 0.1 mL of RMG at d 28 posthatch.
6
BW28 BW is average chicks at 28 days before challenge; BW35 is average chicks at 35 day of age (7
days post-challenge); BWG35 is average BW gain from 28 to 35 day; BW42 is average chicks at 42 day
of age (14 days post-challenge); BWG42 is average BW gain from 28 to 42 day.

134

Table 5.7
Mean percentage of birds that tested positive for Mycoplasma gallisepticum (MG)
DNA in the choanal cleft at d 35 (D 35 DNA) and at d 42 posthatch (D 42 DNA); and IgM at d
35 (D 35 IgM) and d 42 (D 42 IgM); IgG at d 35 (D 35 IgG) and IgG at d 42 (D 42 IgG)
serologic responses in the serum
Treatment1
In ovo
Diluent
1.66 x 103 CFU
SEM
Challenge
Sham
Challenge
SEM
In ovo×Challenge
DS2
DR3
VS4
VR5
SEM
P-value
In ovo
Challenge
In ovo×Challenge12

D 42
D 35
D 42
D 35
D 42
7
8
9
10
DNA
IgM
IgM
IgG
IgG11
-------------------(%)---------------------------(mg/dL)-----50.00
50.00
0.00
0.00
60.43b
172.57b
a
27.50
37.50
97.50 100.00 647.23
1120.33a
6.66
7.125
5.801
95.733
164.810

D 35 DNA6

5.00
72.50
6.664

10.00
77.50
7.125

47.50
65.00
5.801

-

290.07
417.58
95.733

366.15b
926.75a
164.810

0.00c
45.00b
10.00c
100.00a
9.424

0.00c
55.00b
20.00c
100.00a
10.077

0.00c
30.00b
95.00a
100.00a
8.203

0.00
100.00
100.00
100.00
-

27.20
93.65
552.95
741.50
135.390

28.50
316.65
703.80
1536.85
233.070

0.001
<0.0001
<0.0001

0.084
<0.0001
<0.0001

<0.0001
0.004
0.035

-

<0.0001
0.187
0.526

<0.0001
0.001
0.103

a,b

Different letters denote significant difference within a column at P ≤ 0.05.
Treatments including birds that were either diluent or 1.66 x 103 CFU 6/85MGV in ovo-injected and that
were either sham-challenged or RMG-challenged at d 28 of age.
2
Diluent-injected and sham-challenged (DS) treatments were manually injected with 50 μl of Marek’s
diluent in the amnion (AM) at 18 d of incubation (doi) and were tracheal-gavaged with 0.1 mL of diluent
at d 28 posthatch.
3
Diluent-injected and RMG-challenged (DR) treatments were manually injected with 50 μl of Marek’s
diluent in the AM at 18 doi and were tracheal-gavaged with 0.1 mL of RMG at d 28 posthatch.
4
6/85MG-vaccinated and sham-challenged (VS) treatments were manually injected with 50 μl of Marek’s
diluent in the AM at 18 doi and were tracheal-gavaged with 0.1 mL of diluent at d 28 posthatch.
5
6/85MG-vaccinated and RMG-challenged (VR) treatments were manually injected with 50 μl of Marek’s
diluent in the AM at 18 doi and were tracheal-gavaged with 0.1 mL of RMG at d 28 posthatch.
6
Birds were swabbed at d 35 of age (7 days post-challenge) in the choanal cleft for MG DNA detection
via PCR: n=20 chicks per treatment.
7
Birds were swabbed at d 42 of age (14 days post-challenge) in the choanal cleft for MG DNA detection
via PCR: n=20 chicks per treatment.
8
Birds were bled at d 35 of age (7 days post-challenge) for serum plate agglutination (SPA) to test for
IgM antibodies against MG: n=20 chicks per treatment.
9
Birds were bled at d 42 of age (14 days post-challenge) for serum plate agglutination (SPA) to test for
IgM antibodies against MG: n=20 chicks per treatment.
1
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10

Birds were bled at d 35 of age (7 days post-challenge) for ELISA to test for IgG antibodies against MG:
n=20 chicks per treatment.
11
Birds were bled at d 42 of age (14 days post-challenge) for ELISA to test for IgG antibodies against
MG: n=20 chicks per treatment.
12
Main effects (in ovo or challenge) are considered if interactions are not significant.
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Table 5.8
At 7 days (d) post-challenge, total median inflammation and lymphocytic
mucosal nodule (LM nodules) tracheal and bronchial lesion scores of layer pullets in ovoinjected with diluent or the 6/85MG vaccine (6/85MGV) and subsequently challenged at 4
weeks (wk) of age with the Rlow-strain of MG (RMG)
Trachea lesions

Treatment1

Bronchi lesions

N

Inflammation6

LM Nodules

Inflammation

LM Nodules

DS2

8

0b

0

0b

0

DR3

8

2.0a

0

2.0a

0.50

VS4

8

0b

0

0b

0

VR5

8

0b

0

0b

0

0.046

0.785

0.019

0.086

P-value
1

3

Treatments included birds that were either diluent or 1.66 x 10 CFU 6/85MGV in ovo-injected and that
were either sham-challenged or RMG-challenged at d 28 of age.
2
Diluent-injected and sham-challenged (DS) treatments were manually injected with 50 μl of Marek’s
diluent in the amnion (AM) at 18 d of incubation (doi) and were tracheal-gavaged with 0.1 mL of diluent
at d 28 posthatch.
3
Diluent-injected and RMG-challenged (DR) treatments were manually injected with 50 μl of Marek’s
diluent in the AM at 18 doi and were tracheal-gavaged with 0.1 mL of RMG at d 28 posthatch.
4
6/85MG-vaccinated and sham-challenged (VS) treatments were manually injected with 50 μl of
6/85MGV in the AM at 18 doi and were tracheal-gavaged with 0.1 mL of diluent at d 28 posthatch.
5
6/85MG-vaccinated and RMG-challenged (VR) treatments were manually injected with 50 μl of
6/85MGV in the AM at 18 doi and were tracheal-gavaged with 0.1 mL of RMG at d 28 posthatch.
6
Inflammation sites were composed of histocytes, lymphocytes, and heterophils.
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Table 5.9 At 14 days (d) post-challenge, total median inflammation and lymphocytic
mucosal nodule (LM nodules) tracheal and bronchial lesion scores of layer pullets in ovoinjected with diluent or the 6/85MG vaccine (6/85MGV) and subsequently challenged at 4
weeks (wk) of age with the Rlow-strain of MG (RMG)
Trachea lesions

Treatment1

Bronchi lesions

N

Inflammation6

LM Nodules

Inflammation

LM Nodules

DS2

8

0b

0b

0b

0b

DR3

8

2.0a

2.0a

2.0a

2.0a

VS4

8

0b

0b

0b

0b

VR5

8

0b

0b

0b

0b

0.001

<0.0001

0.005

0.006

P-value
1

Treatments included birds that were either diluent or 1.66 x 103 CFU 6/85MGV in ovo-injected and that
were either sham-challenged or RMG-challenged at d 28 of age.
2
Diluent-injected and sham-challenged (DS) treatments were manually injected with 50 μl of Marek’s
diluent in the amnion (AM) at 18 d of incubation (doi) and were tracheal-gavaged with 0.1 mL of diluent
at d 28 posthatch.
3
Diluent-injected and RMG-challenged (DR) treatments were manually injected with 50 μl of Marek’s
diluent in the AM at 18 doi and were tracheal-gavaged with 0.1 mL of RMG at d 28 posthatch.
4
6/85MG-vaccinated and sham-challenged (VS) treatments were manually injected with 50 μl of
6/85MGV in the AM at 18 doi and were tracheal-gavaged with 0.1 mL of diluent at d 28 posthatch.
5
6/85MG-vaccinated and RMG-challenged (VR) treatments were manually injected with 50 μl of
6/85MGV in the AM at 18 doi and were tracheal-gavaged with 0.1 mL of RMG at d 28 posthatch.
6
Inflammation sites were composed of histocytes, lymphocytes, and heterophils.
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CHAPTER VI
SUMMARY
The effects of the in ovo-injection of 6/85MG in the AM and AC on HI, hatch residue,
posthatch performance, and bird serology were determined in Chapter 3. The 6/85MG vaccine
caused no layer embryo or hatched chick mortalities when injected into the AM at a dosage of
1.73 x 102 CFU. However, an FMG vaccine at 2.4 x 102 CFU has been reported to significantly
increase layer embryo and hatchling mortalities (Elliott et al., 2017). The 6/85MG vaccine
caused no total mortality through d 21 posthatch when injected in the AM at a 1.73 x 102 CFU
dosage. In addition, a live 6/85MG vaccine injected in the AM at 1.73, 1.73 x 102, or 1.73 x 104
CFU dosage levels did not result in changes in BW or BWG through d 21 posthatch in
comparison to non-injected controls, whereas in the study by Elliott et al. (2017), FMG at similar
dosages resulted in significant depressions in posthatch BW and BWG in comparison to control
treatments. Our findings revealed that a 1.73 x 104 CFU dosage level of 6/85MG resulted in
greater embryo and early posthatch mortalities when injected in the AM, whereas the other
treatment groups tested had no adverse effect. Furthermore, the AM site of injection was found
to be more effective compared to the AC. This was confirmed by the MG DNA, IgM, and IgG
results when 6/85MG was injected at 18 doi. When the injected in the AM, the 1.73 x 102 and
1.73 x 104 CFU treatment groups caused a humoral response in the pullets at 3 wk posthatch.
However, when injected in the AM, the 1.73 x 104 CFU treatment caused a higher hatched chick
mortality at hatch (22 doi) when compared to the other treatment groups.
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In chapter 4, the in ovo injection of ts-11MGV at 18 doi had no negative impact on the HI
and posthatch immunity of layers. However, it is possible that physiological (organ and blood)
variables that were not investigated in this study may have played a role in the negative effects
that the in ovo ts-11MGV had on BWG21. Although ts-11MG is relatively avirulent in
comparison to other vaccine strains of MG such as FMG, the embryo appears to be more
sensitive to ts-11MG when applied in ovo rather than as an eye drop in the pullet phase. This was
evidenced by the decrease in BWG21 in the group that received the highest dosage. This delayed
effect may be due to the fact that the ts-11MGV requires a longer time for systemic colonization
due to its low level of virulence. The ts-11MG was not transmitted from vaccinated to sentinel
birds at both the hatch and posthatch periods and no subsequent MG DNA or serology responses
were detected. This may result in a weak vaccination consistency among all birds in a flock
when ts-11MG is applied in ovo. Because transmission of an MG vaccine between birds in a
flock is important for total flock protection, this is a matter of concern for the in ovo use of ts11MGV. Therefore, ts-11MG may not be a good candidate for in ovo injection for subsequent
protection of commercial layer flocks against field-strain MG infections.
In chapter 5, the effects of the in ovo-injection of 6/85MGV in the AM on HI, hatch
residue, posthatch performance, and bird serology were determined. In addition, pullets received
an overlay gavage-inoculation of RMG at d 28 of age posthatch to determine if 6/85MGV
administered by in ovo injection provides early protection against field-strain infections and
shows minimum adverse effects and higher levels of antibody production. Our findings revealed
that a 1.66 x 103 CFU dosage level of 6/85MGV resulted in greater embryo hatchability and
posthatch performance in comparison to controls when injected in the AM. Furthermore, a 1.66 x
103 CFU injection in the AM was found to be more effective when compared to a 1.73 x 104
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CFU dosage (Chapter 3). This was confirmed by the MG DNA, IgM, and IgG results when
6/85MGV was injected at 18 doi. When the injected in the AM, the 1.66 x 103 CFU treatment
group exhibited a humoral response at d 28 posthatch, with no negative impact on chick
mortality. However, in the previous study (Chapter 3), when injected in the AM, the 1.73 x 104
CFU treatment caused a higher hatched chick mortality when compared to the other treatment
groups. Trachea and bronchi lesion scores of pullets were significantly affected when they were
inoculated at d 28 of age with RMG, but birds that were in ovo-vaccinated with 6/85MGV
exhibited no significant microscopic lesions due to an RMG challenge. These results indicate
that the 1.66 x 103 CFU treatment injected in the AM provides protection against MG virulent
strain infections during the pullet phase and would be the best candidate for pragmatic
commercial application. This is further supported by the fact that it did not lead to embryo and
posthatch chick mortalities, but at the same time elicited a humoral response.
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